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Abstract
Correction of monogenic heritable diseases by gene augmentation using adeno-associated viral vectors
has made substantial progress in treating diseases caused by genes whose coding sequences are within
the capacity of the vector. To treat diseases caused by large genes whose coding sequences exceed this
capacity, alternate strategies need to be developed. In this study, I evaluated the strategy of pre-mRNA
trans-splicing for correction of two large genes that cause retinal degeneration: CEP290, which principally
causes Leber Congenital Amaurosis type 10, and ABCA4, which principally causes Stargardt disease. To
investigate if such an approach could be used to develop a treatment for these large genes, I designed a
workflow to rapidly analyze DNA coding sequences and determine a target region that would allow for
maximum correction of each gene. I then investigated these regions with a reporter gene (green
fluorescent protein (GFP)) reconstitution assay to find efficacious binding domains for directing premRNA trans-splicing molecules to the target sequences. I demonstrated endogenous gene editing of
CEP290 pre- mRNA in vitro in HEK293T cells, as well as in vivo in photoreceptors of a mini-CEP290 mouse
model following sub-retinal injection. I also identified a putative binding domain to edit ABCA4. However,
a lack of models where ABCA4 is expressed limited my ability to assess endogenous splicing with this
construct. Therefore, I worked to develop such model systems. I conducted a pilot study of ABCA4
expression where dCas9-VPR activated the endogenous ABCA4 locus in HEK293T cells and identified a
118 kDa variant of ABCA4 that is expressed in HEK293T, Y79, and WERI cells. Finally, I derived fibroblasts
from a macaque that had macular spots and characterized two novel ABCA4 mutations in these cells.
Collectively, my thesis work provides a paradigm for (1) generating trans-splicing molecules that can be
used to treat mutations in large genes and (2) developing model systems where preclinical investigations
into gene therapy strategies can be performed.
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ABSTRACT

TAILORING BIG GENES TO SMALL CAPSIDS: DEVELOPING PRE-MRNA TRANS-SPLICING
THERAPIES TO TREAT GENETIC RETINAL DISEASES
Scott Joseph Dooley
Jean Bennett
Correction of monogenic heritable diseases by gene augmentation using adeno-associated viral
vectors has made substantial progress in treating diseases caused by genes whose coding
sequences are within the capacity of the vector. To treat diseases caused by large genes whose
coding sequences exceed this capacity, alternate strategies need to be developed. In this study, I
evaluated the strategy of pre-mRNA trans-splicing for correction of two large genes that cause
retinal degeneration: CEP290, which principally causes Leber Congenital Amaurosis type 10, and
ABCA4, which principally causes Stargardt disease. To investigate if such an approach could be
used to develop a treatment for these large genes, I designed a workflow to rapidly analyze DNA
coding sequences and determine a target region that would allow for maximum correction of each
gene. I then investigated these regions with a reporter gene (green fluorescent protein (GFP))
reconstitution assay to find efficacious binding domains for directing pre-mRNA trans-splicing
molecules to the target sequences. I demonstrated endogenous gene editing of CEP290 premRNA in vitro in HEK293T cells, as well as in vivo in photoreceptors of a mini-CEP290 mouse
model following sub-retinal injection. I also identified a putative binding domain to edit ABCA4.
However, a lack of models where ABCA4 is expressed limited my ability to assess endogenous
splicing with this construct. Therefore, I worked to develop such model systems. I conducted a pilot
study of ABCA4 expression where dCas9-VPR activated the endogenous ABCA4 locus in
HEK293T cells and identified a 118 kDa variant of ABCA4 that is expressed in HEK293T, Y79, and
WERI cells. Finally, I derived fibroblasts from a macaque that had macular spots and characterized
two novel ABCA4 mutations in these cells. Collectively, my thesis work provides a paradigm for (1)
generating trans-splicing molecules that can be used to treat mutations in large genes and (2)
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developing model systems where preclinical investigations into gene therapy strategies can be
performed.
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CHAPTER 1 Introduction

A brief history of gene therapy
The field of gene therapy has made substantial progress recently with numerous clinical
trials showing efficacy and safety when recombinant adeno-associated viruses are used as a vector
to deliver a therapeutic molecule to treat autosomal recessive diseases. Lentiviral vectors have
also garnered acclaim lately for their usage in autologous T cell reprogramming. In 2017, the first
United States Food and Drug Administration (FDA) approved gene therapy products were Kymriah
(Novartis), Yescarta (Gilead), and Luxturna (Spark Therapeutics). While Kymriah and Yescarta are
ex vivo modified T-cells that target blood borne cancers, Luxturna is a product that acts as a
canonical gene therapy agent and delivers the coding sequence of a gene to the retina in vivo in a
genetically aberrant patient. Supplementing an aberrant gene with an exogenous non-mutated
copy is known as gene replacement therapy or gene augmentation because the endogenous copy
remains present.
The current state of gene therapy and its ability to alter the nucleic acid profile of a cell
rises on the shoulders of over 150 years of research into the mechanisms by which traits pass from
one generation to the next. The findings of Gregor Mendel, published in 1865, laid the foundation
for patterns of inheritance (Abbott & Fairbanks, 2016). Friedrich Miescher then teased out the
existence of nucleic acids (Dahm, 2005). Oswald Avery, Colin MacLeod and Maclyn McCarty
deciphered that nucleic acids, not amino acids, were the molecules that could carry traits between
organisms (Avery, MacLeod, & McCarty, 1944). Rosalind Franklin and Maurice Wilkins utilized Xray crystallography to generate images that helped James Watson and Francis Crick deduce the
double helix and base pairing rules that led to a model of nucleic acid replication and the
mechanism by which traits could be duplicated and inherited (Franklin & Gosling, 1953; Watson &
Crick, 1953; Wilkins, Stokes, & Wilson, 1953). These traits were then catalogued as genes and the
field of genetics blossomed.
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Completing a map of the human genome marked a significant milestone in the field of
genetics research (Collins, Lander, Rogers, & Waterson, 2004; Hood & Rowen, 2013; International
Human Genome Sequencing Consortium, 2004). By establishing how and where human genes are
laid out, researchers were able to make leaps forward in understanding what genetic changes
underlie disease, both heritable and spontaneous. Additional large datasets have now been
generated that characterize and facilitate biomedical research. One such master database is the
Human Protein Atlas (www.proteinatlas.org), which contains several datasets including tissue
localization, cellular protein expression, and RNA expression profiles of common cell lines (Uhlen
et al., 2015). These databases, coupled with the expanding availability of processor power and
affordable whole exome and whole genome sequencing, have ushered in the era of personalized
medicine.
As the Human Genome Project was churning out a more complete understanding of human
genetics, the first gene therapy trials were underway for gene augmentation with retroviral and
adenoviral vectors. However, the 1999 death of Jesse Gelsinger, a subject in a liver gene therapy
trial treating a deficiency of ornithine transcarbamylase, and the unintended consequence of driving
leukemia during a 2002 trial for X-linked severe combined immunodeficiency syndrome caused the
FDA to call a halt to these and several similar trials (Check, 2003; Kohn, Sadelain, & Glorioso,
2003; Wilson, 2009). These severe adverse events slowed the overall progress of gene therapy
and brought profound changes to the field, including enhancing the considerations that researchers
must abide by when planning a clinical trial. However, research has continued to find safer vector
alternatives to the adenovirus and retroviruses used in these trials and to evaluate alternative
strategies in general, leading to a recent boom in gene therapy successes.

The eye is an ideal target for pioneering studies
The eye represents an ideal environment to explore and improve gene therapy strategies.
The eye has the advantage of a limited immune response due to a high concentration of molecules
which can dampen immune response, and, as an extension of the nervous system, the eye is
isolated by the blood-retina barrier, which consists of the non-fenestrated vascular retinal
2

endothelial cells and the retinal pigment epithelium (Willett & Bennett, 2013). Contrary to systemic
delivery for a disease target such as skeletal muscle, the eye is a small isolated space. Thus,
smaller volumes of vector can be locally administered and the injection site can be visualized noninvasively to monitor inflammation and reactions to the injection (Samiy, 2014).
As evidence of the utility of the eye as an ideal gene therapy target, the first FDA-approved
gene augmentation therapy, Luxturna, is designed for sub-retinal administration. Data releases
from the Luxturna trials indicated that the treatment was safe and effective, and that administration
to the contralateral eye 1.7 to 3.3 years after the first injection was also safe and effective (Bennett
et al., 2012; Drack et al., 2016; Maguire et al., 2008). Currently, more than two dozen other trials
are ongoing that target transgenes to retinal tissue for diseases including choroideremia, X-linked
retinoschisis and CNGB3 achromatopsia (Bennett, 2017). All of these trials employ traditional gene
augmentation strategies which take advantage of adeno-associated virus.

Adeno-associated virus
Adeno-associated virus (AAV) was first isolated as a secondary particle in adenovirus
preparations (Atchison, Casto, & Hammon, 1965). The associated virus could only replicate in the
presence of adenovirus. Additionally, while adenovirus is a large virus of 70-90 nanometers
diameter, AAV is only 20 nanometers diameter. Vigorous studies identified that AAV contains two
flanking inverted terminal repeat sequences (ITRs) and two principle genes, Rep and Cap,
comprising a total single stranded DNA genome of approximately 4,700 nucleotides (Pereira,
McCarty, & Muzyczka, 1997; Srivastava, Lusby, & Berns, 1983). Rep is required for replication of
the viral genome and binds to the ITRs while Cap allows for production of the capsid proteins.
Additional studies determined that recombinant AAV (rAAV) could be produced by flanking a
transgene with the ITR sequences, and, in the presence of adenovirus particles and the Rep and
Cap genes in trans, infectious AAV genomes could be produced that contained the transgene
(Tratschin, West, Sandbank, & Carter, 1984).
Isolating the specific adenovirus genes required for AAV production yielded further
improvements to the utility of rAAV. When the Rep and Cap genes are delivered in trans with a
3

rAAV proviral plasmid and a third plasmid containing the isolated required adenovirus elements,
recombinant viral genomes could be produced at high titers (Ferrari, Xiao, McCarty, & Samulski,
1997; Thrasher et al., 1995; Xiao, Li, & Samulski, 1998). This triple transfection recombinant AAV
production method has been approved for the creation of vectors used in clinical trials, including
for the production of Luxturna (Mingozzi & High, 2011).
The serotype and thus tropism, or target specificity, of rAAV is specified by variations in
the Cap gene. Additionally, the selection of Cap can be independent from the ITR serotype,
resulting in pseudotyping. This is often annotated as the ITR serotype, a forward slash, and the
Cap serotype, e.g. AAV2/8, indicating that the ITRs were derived from AAV serotype 2 with a
genome encapsulated in an AAV serotype 8 capsid (Sharma, Ghosh, Hansen, Newman, & Mohan,
2010; Yan, Zak, Zhang, & Engelhardt, 2005). Importantly, the Rep gene used in rAAV production
must match the ITR serotype of the proviral plasmid (Beltran et al., 2010; Yan et al., 2005).
The decision of which virus to utilize in a study includes considerations of tropism and the
immunogenicity of viral vectors. AAV serotypes have been identified with various tropism to many
tissues, and this number continues to grow as the search for novel serotypes moves forward
(Lisowski, Tay, & Alexander, 2015; Srivastava, 2016; Zincarelli, Soltys, Rengo, & Rabinowitz,
2008). Additionally, rAAV induces a nominal immune response when delivered locally into tissues
including liver and muscle (Ferreira, Petry, & Salmon, 2014; Mingozzi & High, 2013; Ramos &
Chamberlain, 2015; Rogers & Herzog, 2015). Importantly, this response is particularly muted when
rAAV is administered locally within the eye (Cideciyan, 2010; Willett & Bennett, 2013). This safety
profile has carried through to clinical trials with administration of rAAV to humans (Simonelli et al.,
2010). Research is ongoing to minimize immunogenicity of rAAV, which may help future studies in
tissues that are not immune privileged (Calcedo & Wilson, 2016).
For gene augmentation strategies like Luxturna, a promoter, a transcriptional terminator,
and the complete coding DNA sequence (CCDS) of the transgene are delivered via viral
transduction of target cells (Mingozzi & High, 2011). Luxturna specifically encodes Retinal Pigment
Epithelium-Specific Protein 65 kDa (RPE65), which is associated with Leber Congenital Amaurosis
type 2 and retinitis pigmentosa (Maguire et al., 2008). This particular target was selected for early
4

studies due to the pathology being both monogenic and correlated with a gene with a relatively
small CCDS (Maguire et al., 2008; Simonelli et al., 2010). Mutations in RPE65 were identified in
1997 as a monogenic cause for Leber Congenital Amaurosis, and animal data supported rAAVmediated rescue of disease phenotype when delivering the CCDS of RPE65 (Acland et al., 2001;
Gu et al., 1997; Marlhens et al., 1997).
Early animal studies indicated that a high level of expression would be desired, therefore
the researchers designed a recombinant AAV genome that includes the AAV serotype 2 ITRs
flanking the RPE65 CCDS with a cytomegalovirus enhancer and chicken beta-actin promoter. This
enhancer and promoter combination is known as the CAG promoter and drives strong, ubiquitous
expression in many tissues including non-human primate retina (Sawicki, Morris, Monks, Sakai, &
Miyazaki, 1998; Stieger et al., 2006). Additionally, a bovine growth hormone poly-adenylation signal
was included to terminate transcription and encourage rapid pre-mRNA processing (Goodwin &
Rottman, 1992). While this is ideal to strongly drive expression of RPE65, one consideration for
future therapies is that overexpression of certain proteins can be detrimental for the cell, and
alternative promoters along with other genome elements may need to be used.
The strategy of rAAV gene augmentation can be applied to many potential diseaseassociated genes, but a size limitation is imposed by the physical constraints of the capsid volume
(Grieger & Samulski, 2005). This limitation manifests as reduced efficiency of rAAV production and
reduced transduction efficiency when the viral genome exceeds 5,000 nucleotides (Wu, Yang, &
Colosi, 2010). Excluding the CCDS, the combination of the elements required for expression
reduces the effective packaging size of rAAV to approximately 4,000 nucleotides. In the case of
RPE65, this effective limit was not an exclusion factor, but expanding this gene augmentation
paradigm to other disease-associated genes will present new challenges. With the success of
Luxturna at demonstrating gene augmentation, this strategy can be applied to other targets;
however, it becomes evident that not all genes are within the effective limit. Within retinal disease
associated genes alone, many essential genes exceed this limitation.

5

Big genes
To evaluate the extent of the impact of the size limitation of rAAV on ocular gene therapy,
I began by aggregating a list of all vision-associated genes that were reported in a retinal gene
database (https://sph.uth.edu/retnet/). In collaboration with Osama Ahmed, we cross-referenced
this list against the Ensembl Genome Browser BioMart tool and extracted all characterized
transcripts that correlated with a clinically defined phenotype and had a known primary protein
coding DNA sequence greater than 4500 nucleotides (Smedley et al., 2015). Using this information,
we generated a table of large retinal disease associated genes and their associated phenotype
(Table 1.1). Since these genes are too large for their entire CCDS to fit in recombinant AAV, I
dubbed them “big genes”. Many of these genes are causative for the most prevalent sub-types of
retinal and macular degeneration (Figure 1.1).

Retinitis Pigmentosa

Leber Congenital Amaurosis

Cone-rod dystrophy

Figure 1.1 Prevalence of retinal and macular degeneration associated genes. Genes with coding
sequences too large for traditional rAAV gene augmentation strategies are highlighted in pink. Figure
adapted from den Hollander, Black, Bennett, & Cremers 2010.

Throughout my dissertation, I worked to establish a paradigm for the treatment of retinal
diseases caused by genes too large to be packaged in rAAV. I first evaluated the strategies that
have been suggested for “big genes” that use other delivery approaches (Table 1.2) and those that
employ rAAV beyond traditional gene augmentation (Table 1.3). Each alternative strategy offers
advantages and disadvantages. These comparisons are presented in the respective tables to
outline the caveats of each approach. With these comparisons, I determined which approach would
have a high likelihood of fulfilling an unmet need.
6

Gene
Symbol

CCDS
Phenotype and Disease Associations
Length (nt)

Diease Association
Source Name

Gene Description

ABCC6

4512

DDG2P, MIM morbid,
Orphanet

ATP binding cassette ENST00000205557
subfamily C member 6

TRPM1

4812

- Arterial Calcification Generalized Of Infancy 2
- Pseudoxanthoma Elasticum
- Generalized Arterial Calcification Of Infancy
- Pseudoxanthoma Elasticum
- Night Blindness Congenital Stationary Type 1C
- Cellular Response To Light Stimulus
- Detection Of Light Stimulus Involved In Visual Perception
- G-Protein Coupled Glutamate Receptor Signaling Pathway

DDG2P, GOA, MIM
morbid, Orphanet

transient receptor
ENST00000397795
potential cation
channel, subfamily M,
member 1

LRP5

4848

DDG2P, GOA

LDL receptor related
protein 5

CC2D2A

4863

- Endosteal Hyperostosis Worth Type (Wenhy)
- High Bone Mass Trait (Hbm)
- Osteopetrosis Autosomal Dominant Type 1 (Opta1)
- Osteoporosis-Pseudoglioma Syndrome (Oppg)
- Vitreoretinopathy Exudative Type 4 (Evr4)
- Adipose Tissue Development
- Bone Marrow Development
- Coach Syndrome
- Meckel Syndrome Type 6
- Joubert Syndrome 9, with/without hepatic and/or oculorenal
defects

DDG2P, MIM morbid,
Orphanet

coiled-coil and C2
ENST00000503292
domain containing 2A

C3

4992

- Complement Activation
- Positive Regulation Of Apoptotic Cell Clearance
- Complement Component 3 Deficiency Autosomal Recessive
- Hemolytic Uremic Syndrome Atypical Susceptibility To 5
- Macular Degeneration Age-Related 9 Susceptibility To
- Atypical Hemolytic Uremic Syndrome With C3 Anomaly

GOA, MIM morbid,
Orphanet

complement
component

RIMS1

5079

- Cone-Rod Dystrophy 7

MIM morbid, Orphanet

IFT172

5250

- Jeune Syndrome
- Mainzer-Saldino Syndrome
- Saldino-Mainzer Syndrome
- Retinitis Pigmentosa 71
- Short-Rib Thoracic Dysplasia 10 With Or Without Polydactyly
- Bardet-Biedl Syndrome

DDG2P, MIM morbid,
Orphanet

regulating synaptic
ENST00000521978
membrane exocytosis
1
intraflagellar transport ENST00000260570
172

COL11A1

5421

- Fibrochondrogenesis
DDG2P, GOA, MIM
- Stickler Syndrome Type II
morbid, Orphanet
- Detection Of Light Stimulus Involved In Visual Perception
- Detection Of Mechanical Stimulus Involved In Sensory
Perception Of Sound
- Fibrochondrogenesis 1, Marshall Syndrome
- Autosomal Dominant Myopia-Midfacial Retrusion-Sensorineural
Hearing Loss-Rhizomelic Dysplasia Syndrome

collagen, type XI,
alpha 1

ENST00000370096

TUBGCP6 5460

- Microcephaly And Chorioretinopathy Autosomal Recessive 1,
with/without mental retardation

DDG2P, MIM morbid,
Orphanet

tubulin gamma
complex associated
protein 6

ENST00000248846

KIAA1549

ENST00000440172

5805

Ensembl Transcript
ID

ENST00000294304

ENST00000245907

- Pilocytic Astrocytoma

Orphanet

KIAA1549

CACNA1F 5934

- Detection Of Light Stimulus Involved In Visual Perception
- Aland Islands Eye Disease
- Cone-Rod Dystrophy X-Linked 3
- Night Blindness Congenital Stationary Type 2A

GOA, MIM morbid,
Orphanet

calcium channel,
ENST00000376265
voltage-dependent, L
type, alpha 1F subunit

SNRNP200 6411

- Retinitis Pigmentosa 33

MIM morbid, Orphanet

RP1

6471

- Hypertriglyceridemia Familial
- Retinitis Pigmentosa 1

MIM morbid, Orphanet

small nuclear
ENST00000323853
ribonucleoprotein, U5
200kDa subunit
retinitis pigmentosa 1 ENST00000220676
(autosomal dominant)

MYO7A

6528

DDG2P, GOA

myosin VIIA

ABCA4

6822

- Deafness Autosomal Recessive Type 2
- Usher Syndrome Type 1B
- Calmodulin Binding
- Detection Of Light Stimulus Involved In Visual Perception
- Detection Of Mechanical Stimulus Involved In Sensory
Perception Of Sound
- Equilibrioception
- Sensory Perception Of Light Stimulus
- Cone-Rod Dystrophy 3
- Macular Degeneration Age-Related 2
- Retinitis Pigmentosa 19
- Stargardt Disease 1

MIM morbid, Orphanet

ATP binding cassette ENST00000370225
subfamily A member 4

PRPF8

7008

- Retinitis Pigmentosa 13

MIM morbid, Orphanet

CEP290

7440

DDG2P, GOA

pre-mRNA processing ENST00000304992
factor 8
centrosomal protein
ENST00000552810
290kDa

VCAN

10191

USH2A

15609

HMCN1

16908

- Bardet-Biedl Syndrome Type 14 (Bbs14)
- Joubert Syndrome Type 5 (Jbts5)
- Leber Congenital Amaurosis Type 10 (Lca10)
- Meckel Syndrome Type 4 (Mks4)
- Senior-Loken Syndrome Type 6 (Slsn6)
- Negative Regulation Of Establishment Of Protein Localization To
Plasma Membrane
- Wagner Disease
- Wagner Vitreoretinopathy
- Maintenance Of Organ Identity
- Photoreceptor Cell Maintenance
- Sensory Perception Of Light and Sound
- Retinitis Pigmentosa 39
- Usher Syndrome Type 2A
- Macular Degeneration Age-Related 15 Susceptibility

ENST00000458637

MIM morbid, Orphanet

versican

GOA, MIM morbid,
Orphanet

Usher syndrome 2A
ENST00000307340
(autosomal recessive,
mild)

ENST00000265077

MIM morbid

hemicentin 1

ENST00000271588

Table 1.1 Retinal disease associated genes with large CCDS
7

Vector Name

Packaging Expression United States FDA Clinical Trial
Capacity Stability
Status

Trial Results and Additional Comments

Adeno-associated
virus

5,000

Short term - NCT02652780 / NCT02652767
and stable Phase III ND4 Intravitreal Recruiting.
- NCT00891306 / NCT01109498
Phase II/III LPL Intramuscular Halted.
- Numerous Phase I and II studies.

- Luxturna approved for commercial sale to
treat LCA II - RPE65.
- Numerous Phase I and II studies within the
context of the eye, subretinal and intravitreal,
due to limited immune response.
- Secondary prinicipal targets are
intramuscular delivery for hemophilia
disorders.

Lentivirus

8,000

Stable

- NCT01896102 Phase II/III ABCD1
ex-vivo HSCs followed by transplant
- Ongoing.
- NCT01367444/NCT01736592
Phase I/IIa ABCA4 subretinal Completed, under followup.
- NCT02234934 Phase I/II CGD exvivo T-cells followed by infusion Recruiting.

- Kymriah and Yesterna approved for
commercial sale for autologous T-cell
reprogramming with CD19 CAR generation
- Numerous studies for cancer immunotherapy
focusing on ex viv o transduction of T-cells to
introduct chimeric antigen receptors.

Retrovirus

8,000

Stable

- NCT01129544 Phase I/II Gamma
Retrovirus trial for treating X linked
SCID.

- Retroviruses fell out of favor following reports
of leukemia due to insertional mutagenesis in
patients being treated for SCID.

Naked DNA with
electroporation

N/A

Short term - NCT02348320 Phase I polyepitope - Several completed Phase I studies. Followup
vaccine, Intramuscular
data shows good tolerability but minimal
electroporation, Recruiting.
efficacy.
- NCT00536627 Phase II study of
DNA vaccine for Hepatitis B.

Nanoparticle

N/A

Short term - NCT01437007 Phase I lipid
nanoparticle delivered siRNA to treat
liver cancers.
- NCT02314052 Phase II double
stranded RNA delivered via lipid
nanoparticle to treat
hepatocarinoma.

Gene gun

N/A

Short term - NCT988559 pilot study using gene - Allows for exact delivery dosage of DNA to
gun to deliver DNA vaccine in
target, however, very few studies conducted
patients with HPV16+CIN2/3.
on efficacy.

Transfection

N/A

Short term - Numerous Phase I/II studies for
cancer immunotherapy focusing on
ex vivo transfection of dendridic
cells.
- Several trials for vaccine efficacy
following transfection of antigens.

- Modest efficacy of transduction and good
tolerability.
- Do not have issue of immunologic response
unlike AAVs.

Table 1.2 Summary of alternative gene delivery methods
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Table 1.3 Alternative AAV based gene augmentation strategies
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Truncations and Mini-genes

- Final product is a complete
gene

- Requires a gene that can
function while lacking one or
more domains
- Novel peptide epitopes may
induce immune responses

Single vector approach
- 5' ITR
- Promoter
- Engineered CDS
- polyadenylation signal
- 3' ITR

~4,000 nt

Disadvantages

Elements required

Available CDS size

- None

Advantages

Cellular process utilized

Cis -splicing Vectors

Overlapping Vectors

~8,000 nt combined

3' Vector
- 5' ITR
- 3' splice site
- 3' end of CDS
- polyadenylation signal
- 3' ITR

Two vector approach
5' Vector
- 5' ITR
- Promoter
- 5' end of CDS
- 5' splice site
- 3' ITR

- Cannot treat dominant
- Requires co-transduction
- Low efficacy due to
dependence on fraction of
concatamers that are in correct
orientation
- FDA approval may require
delivery of either and both
vectors (larger trial requirements)

- Final product is a complete
gene

~7,600 nt combined

3' Vector
- 5' ITR
- Overlap of CDS between 5'
and 3' halves
- 3' end of CDS
- polyadenylation signal
- 3' ITR

Two vector approach
5' Vector
- 5' ITR
- Promoter
- 5' end of CDS
- Overlap of CDS between 5'
and 3' halves
- 3' ITR

- Cannot treat dominant
- Requires co-transduction with
and recombination between
vectors

- Final product is a complete
gene

- Cis-splicing between
- Homologous recombination
complementary vectors that form between overlapping vectors
concatemers

Fragmented Vectors

Unknown

"Single" vector approach
- 5' ITR
- Promoter
- CDS random fragments
- polyadenylation signal
- 3' ITR

- Cannot treat dominant
- Requires co-transduction with
and recombination between
complementary vector fragments
- FDA may not approve
inconsistent heterogeneous
mixtures of fragments between
manufacturing lots

- Final product is a complete
gene
- Less engineering required due
to stochastic generation of
variants

- Homologous recombination
between vectors with variable
CDS fragments

- Regulated by endogenous
expression
- Can treat dominant

~3,500 nt

- Gene target region must be
transcriptionally active

3' Vector
- 5' ITR
- Recombinogenic region
- Overlap of nucleotides
between 5' and 3' halves
- 3' splice site
- 3' end of CDS
- polyadenylation signal
- 3' ITR

~7,000 nt

Single vector targeting
endogenous expression
- 5' ITR
- promoter
- 5' end of CDS
- 5' splice site
- linker
- target intron binding domain
- *degradation signal
- 3' ITR

Two vector approach
5' Vector
- 5' ITR
- Promoter
- 5' end of CDS
- 5' splice site
- Recombinogenic region
- Overlap of nucleotides
between 5' and 3' halves
- 3' ITR

- Cannot treat dominant
- Incomplete coverage of gene
- Requires co-transduction
- Cannot treat deletions of
- FDA approval may require
target region
delivery of either and both
vectors (larger trial requirements)

- Final product is a complete
gene
- More effective due to multiple
pathways for complete
reconstitution

Hybrid trans -splicing and
5' pre-mRNA trans -splicing
recombinogenic vectors
- Trans -splicing between vectors - Trans-splicing to endogenous
- Homologous recombination
pre-mRNA at a target locus
between vectors
- Cis-splicing between
complementary vectors that form
concatemers

3' pre-mRNA trans -splicing

~3,500 nt

- Gene target region must be
transcriptionally active

Single vector targeting
endogenous expression
- 5' ITR
- target intron binding domain
- linker
- 3' splice site
- 3' end of CDS
- polyadenylation signal
- 3' ITR

- Incomplete coverage of gene
- Cannot treat deletions of
target region

- Regulated by endogenous
expression
- Can treat dominant

- Trans-splicing to endogenous
pre-mRNA at a target locus

Non-AAV strategies for transgene delivery
In contrast to AAV, lentivirus particles contain a double stranded RNA genome that can be
up to 10,000 nucleotides in length and therefore accommodate a much larger CCDS (Balaggan &
Ali, 2012). A recombinant lentivirus genome requires several native viral elements and a capsid
that contains more viral proteins than AAV (Delenda, 2004; Verhoeyen & Cosset, 2004). These
additional necessary elements can invoke an immune response when using lentivirus in immune
competent disease models (Follenzi, Santambrogio, & Annoni, 2007). From a therapeutic
standpoint, immune response to the vector can be mitigated in certain gene therapy applications
such as ex vivo editing of T-cells for cancer immunotherapy (Holzinger, Barden, & Abken, 2016).
Autologous T-cell reprogramming with chimeric antigen receptors has also shown incredible
success (June, O’Connor, Kawalekar, Ghassemi, & Milone, 2018). In addition to cancer
immunotherapy, lentivirus can be used to reprogram certain cell types which can then be delivered
to a target tissue (Belian et al., 2015). The ex vivo modification of hematopoietic stem cells has
additional prospective applications for conditions such as Hunter disease (Simona et al., 2018).
However, ex vivo cell modification cannot be utilized when tissue, such as photoreceptors, cannot
be manipulated outside of the body and re-engrafted.
In vivo, lentivirus delivered by sub-retinal injection was shown to transduce photoreceptors
in neonatal rat pups, but the transduction efficiency was substantially reduced in adults (Miyoshi,
Takahashi, Gage, & Verma, 1997). Lentivirus delivered via sub-retinal injection is hindered by the
interphotoreceptor matrix and poorly transduces photoreceptors (Balaggan & Ali, 2012; Grüter et
al., 2005). Thus, while lentiviral vectors may have a significant role in other targets for gene therapy,
they are not ideal for targeting photoreceptors (Escors & Breckpot, 2010).
The equine infectious anemia virus was able to transduce photoreceptors in neonatal
mouse Abca4-/- models of Stargardt disease when using the full human coding sequence of ABCA4
driven by the constitutive cytomegalovirus or the photoreceptor-specific bovine Rhodopsin
promoters (Kong et al., 2008). Researchers demonstrated safety and bio-distribution assays in
rabbit and macaque animals using this construct (Binley et al., 2013). This construct, dubbed
SAR422459, is currently being evaluated in Phase I/II dose-escalation and follow-up clinical trials
10

sponsored by Sanofi that began enrollment in 2011 and have an expected completion date in 2019
(Clinical Trials ID NCT01367444 and NCT01736592). To date, there have been no public reports
about the status of any subjects who have received SAR422459.
There are also non-viral delivery methods such as naked DNA electroporation,
nanoparticles, gene gun, and transfection. However, none of these can currently confer tropism
and all have a lack of clinical data. Additionally, an alternative therapeutic approach for the
treatment of heritable ocular disease is cell transplantation. Early proof-of-concept studies in a rat
model of photoreceptor degeneration showed that retinal pigment epithelial cells infected with a
virus expressing a transgene could be transplanted into the sub-retinal space of albino RCS rats
and partially preserve photoreceptors (Dunaief et al., 1995). Recently, pilot studies were performed
with transplantation of human embryonic stem cells into the retinas of Macaca mulatta and Macaca
fascicularis (Shirai et al., 2015). Progress in the field of cell transplantation has been extensively
reviewed, but clinical data is still in early phases with small cohorts and there is not yet a sufficient
body of evidence for efficacy of cell transplantation (Chichagova et al., 2018). Subjects in clinical
trials who were treated with stem cell-derived RPE sheets have shown no adverse events but also
have shown only limited improvements to visual acuity (Kashani et al., 2018; Mandai et al., 2017).
Therefore, after considering the

Mini Gene (Truncations)

Targeted Genomic Recombination

various factors of immune tolerance, size
constraints, tropism, safety, simplicity of
genome engineering, and efficacy, it

X X

Multiple Vectors

became clear that working within the

Pre-mRNA trans-splicing

constraints of rAAV is desirable for
development of gene therapy strategies
X

that

target

photoreceptors.

Multiple

possible approaches have been published

Figure 1.2 Potential partial gene augmentation
strategies using AAV.

and are discussed below (Figure 1.2, Table 1.3).
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Truncations, mini-genes, and homologs
One approach to make big genes fit into small rAAV capsids is to identify and eliminate
repetitive or regulatory domains that are not essential to the core function of the protein. For
example, in a zebrafish model of human blindness, one group reported that providing the N-terminal
region of CEP290 restored vision (Baye et al., 2011). More recently, another group demonstrated
rescue of photoreceptors in a Cep290rd16 mouse model of Leber Congenital Amaurosis type 10
(LCA10) treated with rAAV encoding amino acids 580-1180 of CEP290 (W. Zhang, Li, Su, Gao, &
Khanna, 2018). This finding led to a sponsored research agreement between the University of
Massachusetts Medical School Horae Gene Therapy Center and Orphotech Corporation to
develop this mini-gene platform.
Dystrophin is another intriguing gene for this type of strategy as it contains several
repetitive elements. Rescue in an mdx mouse model of muscular dystrophy has varied depending
on which regions are removed and which are retained (Nelson et al., 2018). Utrophin, a
developmental stage homolog of dystrophin, has also been engineered to a micro-form to function
as a replacement for dystrophin in the mdx mouse (Odom, Gregorevic, Allen, Finn, & Chamberlain,
2008).

Multiple AAV genomes with partial coding DNA sequences
Efforts have been also made to break the coding DNA sequence of a large gene into
fragments across multiple viral genomes (Berger et al., 2016; Carvalho et al., 2017). When applied
to CEP290, two rAAV genomes were designed with either the 5’ or 3’ half of the coding sequence
along with elements required to reconstitute the open reading frame (Trapani et al., 2014). The
limitations of this approach concern 1) efficiency: vectors of each genome must transduce the same
cell and further, the genomes must recombine or undergo concatamerization in the proper
orientation, and 2) potential immunogenicity: both fragments have the potential to produce partial
gene products which may trigger an immune response (McClements, Charbel Issa, Blouin, &
MacLaren, 2016). The multiple vector approach has recently been combined with the mini-gene
approach for treating a single animal of a canine model of Duchenne muscular dystrophy. The dog
12

was treated with a 7-kb canine mini-dystrophin ΔH2-R15 split across two rAAV genomes and
showed protection against stress-induced muscle damage (Kodippili et al., 2017).
Each of the strategies discussed so far are forms of gene augmentation designed to
complement the endogenous sequence and replace its function. Such approaches cannot be
utilized for dominant negative mutations or when regulation of gene expression is required.

Gene editing with endonucleases
Significant improvements to targeted endonucleases have revolutionized the field of gene
engineering. The discovery and conversion of CRISPR/Cas9 into a microbiology tool introduced a
sequence-directed endonuclease that can be directed to nearly any target within the genome (Hsu,
Lander, & Zhang, 2014; Ran et al., 2013). For diseases that are associated with a particularly
prevalent mutation, it may be advantageous to develop a gene editing strategy that can alter the
genomic DNA. Patients with LCA10 frequently have an inversion in the 26th intron which leads to
inclusion of a cryptic exon, dubbed exon X. Researchers have utilized Cas9 to disrupt the cryptic
splice site and thus rescue expression of CEP290 in cell lines derived from these patients by
preventing inclusion of the cryptic exon (Ruan et al., 2017).

Anti-sense oligonucleotides
Anti-sense oligonucleotides have also been evaluated in several settings including LCA10
patient-derived cells. When these molecules were designed to target the cryptic splice site,
researchers observed reduced inclusion of exon X and CEP290 protein levels as closer to samples
obtained from healthy-donors (Collin & Garanto, 2017). A concern with both the Cas9 and the antisense oligonucleotide approaches is that the utility of either method directed at the specific
mutation, in this case CEP290 exon X, may not be as high in compound heterozygous patients or
in patients lacking the IVS26 mutation since the second allele would not benefit from therapy.
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RNA editing by trans-splicing
As a final alternative, delivery of rAAV genomes encoding partial coding DNA sequences
designed to trans-splice to endogenous pre-mRNA is an attractive strategy. This strategy is akin to
the multiple vectors strategy but differs in that a single viral genome is used which targets
endogenous pre-mRNA transcripts to yield a hybrid exogenous-endogenous mRNA. Additionally,
this strategy takes advantage of endogenous expression levels, which is a safety consideration
since CEP290 overexpression may cause toxicity (Burnight et al., 2014).
Trans-splicing was first shown to occur in vitro (Konarska et al., 1985; Solnick, 1985). Since
then, trans-splicing molecules have been demonstrated with 5’, 3’, or internal exon replacement
(Berger et al., 2015; Chao et al., 2003; Koller et al., 2011). Pre-mRNA trans-splicing molecules
have been demonstrated to edit genes across many disease models including cystic fibrosis (X.
Liu et al., 2002, 2005; Mansfield et al., 2000; Puttaraju, Jamison, Mansfield, Garcia-Blanco, &
Mitchell, 1999), muscular dystrophy (Lorain et al., 2013; Monjaret et al., 2014; Trochet, Prudhon,
Jollet, Lorain, & Bitoun, 2016), hypertrophic cardiomyopathy (Mearini et al., 2013; Trochet et al.,
2016), and retinitis pigmentosa 1 (Berger et al., 2015). Some efforts have also been made to apply
trans-splicing to the treatment of cancer cells including through functional repair of p53 in colorectal
cancer cells and hepatocellular carcinoma cells (He, Liao, et al., 2015; He, Liu, et al., 2015).

Thesis aims
Each of these approaches may be beneficial, and selecting an approach to match a gene
and disease requires an empirical analysis backed by knowledge of the genetic mutation and the
coding sequence of the nucleic acid. Delivering a complete coding DNA sequence via a viral vector
is not always an option if the sequence is too large for the vector. However, alternative approaches
broaden the utility of rAAV. For my thesis research, I hypothesized that pre-mRNA trans-splicing
can be adapted to treat the most prevalent forms of retinal degeneration caused by genes
exceeding the capacity of rAAV. In chapter 2 I will show that pre-mRNA trans-splicing can be used
to generate RNA editing in multiple models of CEP290 deficiency. In chapter 3, I will discuss my
development of model systems where trans-splicing approaches can be tested to correct mutations
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in ABCA4. Finally, in chapter 4, in contrast to the technical proof-of-principle targeting of these
trans-splicing approaches, I design algorithms that can be applied to rapidly identify regions of
maximum benefit and generate high-throughput libraries for screening trans-splicing molecules for
any gene. Collectively, my research demonstrates that a trans-splicing approach combined with
AAV delivery can be effective in yielding hybrid edited RNA transcripts for large retinal degeneration
associated genes.
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CHAPTER 2 Pre-mRNA trans-splicing can edit CEP290 mRNA

Introduction
Leber Congenital Amaurosis
Leber Congenital Amaurosis (LCA) is the most severe subset of the set of diseases
classified as retinitis pigmentosa, affecting 1 in 100,000 people. LCA is typically diagnosed in
infants with severely abnormal vision through finding of non-recordable electroretinograms.
Children with LCA have trouble seeing in dim light (nyctalopia), have reduced visual resolution
(visual acuity) and peripheral vision (visual fields) and often have abnormal rotatory eye movements
(nystagmus). Whatever poor vision they have early in life gradually disappears due to the
degenerative component of the disease (Koenekoop, 2004).
There are nearly twenty identified disease-associated genes. Amelioration of one form of
early onset retinal degeneration (LCA Type 2) caused by the gene RPE65 has been demonstrated
following sub-retinal administration of recombinant adeno-associated virus (AAV) encoding the
complete RPE65 coding DNA sequence (Bennett et al., 2016; Russell et al., 2017; Simonelli et al.,
2010). Other forms of inherited retinal degeneration may be amenable to rescue following this
strategy; however, the genes associated with the most prevalent forms of retinal disease exceed
the DNA coding capacity of AAV (Den Hollander, Black, Bennett, & Cremers, 2010). Mutations in
CEP290, the most common cause of LCA, are designated as LCA Type 10 (LCA10), and the
complete coding DNA sequence is 7,440 nucleotides (GeneBank: NM_025114.3). Therefore, it is
necessary to develop a gene therapy strategy that can correct a broad range of mutations in large
genes such as CEP290 with AAV.

Structure and function of CEP290
CEP290 is comprised of 54 exons and encodes a 290 kDa protein. Among other various
domains, CEP290 contains 13 coiled-coiled domains and an ATP/GTP binding site motif (Guo et
al., 2004; Sayer et al., 2006). CEP290 has been shown to bind at multiple cellular locations
including the centriole during interphase and the transition zone of the cilia (Cideciyan et al., 2007;
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Craige et al., 2010; Nagase et al., 1997; Tsang et al., 2008; Valente et al., 2006). Knockdown of
CEP290 suppresses cilia formation and previous work in the Bennett laboratory showed a
microtubule binding region and a membrane binding region, lending further evidence to its function
in cilia stability (Drivas, Holzbaur, & Bennett, 2013; Tsang et al., 2008).
Like many ciliary associated proteins, CEP290 is highly conserved throughout species and
broadly expressed in many cell types (Craige et al., 2010). Mutations in CEP290 not only cause
LCA10, but also have been linked to a variety of other developmental diseases and ciliopathies
including Senior-Loken Syndrome, Joubert Syndrome, and Meckel-Gruber Syndrome (AhdabBarmada & Claassen, 1990; Brancati et al., 2007; den Hollander et al., 2006; Genuardi et al., 1993).
Most LCA10 patients harbor two mutations in CEP290, which are typically compound
heterozygous. The most common mutation in LCA10 is a single nucleotide polymorphism of A to
G within the intron between
CEP290 IVS26 c.2991+1655 A>G
5’SS

exons 26 and 27. This mutation
is

annotated

as

IVS26

Exon 26

Cryptic
3’SS

5’SS

Exon X

3’SS

gtgaGta

Exon 27

c.2991+1655 A>G, hereafter
Exon 26

Exon X

Exon 27

IVS26, and generates a cryptic
splice site leading to inclusion of
a cryptic exon, known as exon
X, which encodes an immediate

Figure 2.1 Illustration of the most prevalent genetic mutation that
causes LCA10. This intron variant sequence (IVS) is an A to G
transition that creates a canonical 5’ splice site (5’ SS). The novel
splice site leads to inclusion of a cryptic exon, exon X. This cryptic
exon encodes a premature stop codon leading to a truncated
protein. Figure adapted from Dooley, et al., 2018

stop codon (Figure 2.1).
Though fully differentiated, light-responsive photoreceptors derived from induced
pluripotent stem cells have yet to be reliably generated, optic cups generated from IVS26
homozygous patients show reduced CEP290 protein, shorter cilia, and other deficits compared to
wild-type cell lines (Parfitt et al., 2016). Additionally, other cell types including primary fibroblasts
show similar phenotypes (Burnight et al., 2014).
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Gene therapy strategies for treating LCA10
Based on the prevalence of IVS26 within LCA10 patients and likely disease pathogenesis
through haploinsufficiency in the retina, several strategies have been developed to specifically
prevent inclusion of cryptic exon X. Several groups have targeted the RNA-directed endonuclease
Cas9 to the cryptic splice site to either alter the sequence or specifically use homology-directed
repair to correct the mutation (Burnight et al., 2017; Ruan et al., 2017). Anti-sense oligonucleotides
have also been evaluated in several settings with IVS26 homozygous patient-derived cells and
shown to reduce inclusion of exon X and restore CEP290 protein levels (Collin & Garanto, 2017).
One concern is that the utility of the Cas9 or anti-sense oligonucleotide methods directed at exon
X may not be as high in compound heterozygous patients or in patients lacking the IVS26 mutation
since the second allele would not benefit from therapy. Lastly, efforts have been made to break the
coding DNA sequence of a large gene into fragments across multiple viral genomes (Berger et al.,
2016; Carvalho et al., 2017). When applied to LCA10, two AAV genomes are designed with either
the 5’ or 3’ half of CEP290 along with elements required to reconstitute the open reading frame
(Trapani et al., 2014). The limitations of this approach concern both efficiency, since vectors of
each genome must transduce the same cell and recombine or undergo concatamerization in proper
orientation, and potential immunogenicity, because either fragment may produce partial gene
products.
Delivery of AAV genomes encoding partial coding DNA sequences designed to trans-splice
to endogenous pre-mRNA is also an attractive strategy. This strategy is akin to the multiple vectors
strategy but differs in that a single viral genome is used which targets endogenous pre-mRNA
transcripts to yield a hybrid exogenous-endogenous mRNA. Additionally, this strategy takes
advantage of endogenous expression levels, which is a safety consideration since CEP290
overexpression may cause toxicity (Burnight et al., 2014). Here, I evaluated the potential of premRNA trans-splicing to edit CEP290 and demonstrated that this approach can be effective in
yielding hybrid RNA both in vitro and in vivo.
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Results
Design of a trans-splicing strategy for CEP290
A strategy to rescue CEP290 should cover as many disease-associated mutations as
possible. Therefore, I wanted to determine the maximum length of a possible partial coding DNA
sequence. I initially designed a hypothetical pre-mRNA trans-splicing molecule consisting of
flanking inverted terminal repeats, the cytomegalovirus immediate early enhancer and promoter, a
canonical 5’ splice site, 20 nucleotides of
Maximum Genome Capacity of AdenoAssociated Virus (AAV)
5’ and 3’ Inverted Terminal Repeats (ITR):
Adeno-associated virus serotype 2

intron spacer sequence, a putative binding
domain and a bovine growth hormone polyadenylation
subtracting

signal
these

sequence.
elements

from

Enhancer and Promoter: e.g.
Cytomegalovirus immediate early (CMVie)

After

Partial coding DNA sequence (PCDS)
5’ splice site with Spacer sequence
(5’SS/Spacer)

the

Putative Binding Domain

maximum 4,700 nucleotides of AAV, the

Transcriptional terminator: e.g. bGH polyadenylation signal (pA)

maximum partial coding DNA sequence

Maximum space for N Length PCDS

4,700
290
584
N
25
~50-200
225
3,376

Figure 2.2 Computational analysis of required
elements for a trans-splicing molecule given
the size limitations of adeno-associated virus.
Figure adapted from Dooley, et al., 2018

(PCDS) for a trans-splicing AAV genome can
be estimated to be between 3,000 and 3,500
nucleotides (Figure 2.2).

For a 5’ pre-mRNA trans-splicing molecule (PTM), the PCDS must end at the 3’ end of an
exon to allow for a 5’ splice site. Therefore, PCDS size increases by the size of the exon proximal
to a target intron. When plotted as a table, the PCDS size is the sum of all coding nucleotides
upstream to the target intron. The first methionine of the open reading frame for CEP290 is encoded
in the second exon. Therefore, the PCDS begins within exon 2 and continues to the stop codon in
exon 54. I generated a table consisting of CEP290 exon numbers, nucleotide length of exons and
introns, and a tally of the coding nucleotides at each boundary (Table 2.1).
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Exon No.

Exon Size

5' PCDS

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

317
129
78
70
47
144
54
21
153
183
90
123
124
170
163
101
88
113
85
143
165
150
116
103
231
174
112
206
152
112
456
165
108
135
267
108
200
214
138
222
123
146
156
124
135
87
165
123
173
142
74
95
80
395

102
180
250
297
441
495
516
669
852
942
1065
1189
1359
1522
1623
1711
1824
1909
2052
2217
2367
2483
2586
2817
2991
3103
3309
3461
3573
4029
4194
4302
4437
4704
4812
5012
5226
5364
5586
5709
5855
6011
6135
6270
6357
6522
6645
6818
6960
7034
7129
7209
7440

3' PCDS

Intron Size

Intron Name

7440
7338
7260
7190
7143
6999
6945
6924
6771
6588
6498
6375
6251
6081
5918
5817
5729
5616
5531
5388
5223
5073
4957
4854
4623
4449
4337
4131
3979
3867
3411
3246
3138
3003
2736
2628
2428
2214
2076
1854
1731
1585
1429
1305
1170
1083
918
795
622
480
406
311
231

565
172
1,391
303
2,358
5,424
599
124
391
658
2,507
946
4,079
720
1,370
72
1,337
1,850
535
2,561
342
2,020
1,967
90
3,663
5,838
2,912
937
1,841
1,240
1,087
1,281
217
1,186
631
616
2,635
952
1,173
352
5,295
331
2,648
4,406
1,202
1,697
809
877
3,130
1,162
593
3,218
939

1-2
2-3
3-4
4-5
5-6
6-7
7-8
8-9
9-10
10-11
11-12
12-13
13-14
14-15
15-16
16-17
17-18
18-19
19-20
20-21
21-22
22-23
23-24
24-25
25-26
26-27
27-28
28-29
29-30
30-31
31-32
32-33
33-34
34-35
35-36
36-37
37-38
38-39
39-40
40-41
41-42
42-43
43-44
44-45
45-46
46-47
47-48
48-49
49-50
50-51
51-52
52-53
53-54

Table 2.1 CEP290 exon and intron boundaries with corresponding partial coding DNA sequence (PCDS)
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To rescue the most common mutations

Exon
Number

Intron
Number

Exon
Size

5' PCDS
Size

Intron
Size

that cause LCA10, at minimum, a 5’ PTM must

23

23-24

116

2483

1967

24

24-25

103

2586

90

be targeted to a region downstream of exon X. By

25
26

25-26
26-27

231
174

2817
2991

3663
5838

26

26-X

174

X

X-27

128

27

27-28

112

3103

28

28-29

206

3309

937

29

29-30

152

3461

1841

30

30-31

112

3573

1240

31

31-32

456

4029

1087

32

32-33

165

4194

1281

definition, exon X breaks intron 26-27 into the
novel introns 26-X and X-27. I determined that
intron X-27 would be 4,188 nucleotides and

1522
4188
2912

Figure 2.3 Analysis of CEP290 exon and intron
boundaries reveals the possible sizes of a 5’
partial coding DNA sequence (PCDS) when
using a 5’ trans-splicing approach to target
various introns. Figure adapted from Dooley, et
al., 2018

would require a 5’ PCDS consisting of 2,991
nucleotides (Figure 2.3). Therefore, I selected
intron X-27 as the region to target and screen for
putative binding domains.

Treatment of cells containing the IVS26 mutation with a trans-splicing AAV genome
targeting intron X-27 (Figure 2.4, top) would result in three predicted outcomes: (1) a fraction of
transcripts splicing normally to generate a wild-type allele, (2) inclusion of exon X via cis-splicing
leading to expected nonsense mediated decay, and (3) the trans-spliced hybrid of 5’ PCDS and
endogenous exons 27-54 with the potential to generate wild-type protein (Figure 2.4, bottom).

AA
PTM pre-mRNA 2,991bp
5’

CEP290 pre-mRNA
5’

Exon 1-26

Intron 26-X

PCDS
3’

Exon X

Exon 27-54

Intron X-27

pA

3’

Intron 26-27

BB
Potential mRNA Outcomes of RNA Editing
Exon 1-26
Exon 1-26

Exon X
PCDS

Exon 27-54

AAAA

cis-wild-type 290.4 kDa CEP290

Exon 27-54

AAAA

cis-mutant

Exon 27-54

AAAA

trans-hybrid

290.4 kDa CEP290

Figure 2.4 Illustrations of trans-splicing outcomes. (A) Schematic of an approach to utilize a 5’ premRNA trans-splicing molecule (PTM) to rescue mutations in CEP290 that are located 5’ to intron X27. The PTM transcript is bound via Watson-Crick base-pairing to the pre-mRNA of a target via a
sequence, known as the binding domain, located at the 3’ end of the PTM and that is reverse
complementary to the target sequence. (B) Three potential splicing outcomes with CEP290 IVS26
following introduction of a 5’ PTM: (1) joining of exon 26 to exon 27 from cis-splicing for the wild-type
junction; (2) inclusion of exon X from cis-splicing (predominant mRNA species with IVS26 present);
(3) joining of the 5’ PCDS to exon 27 from trans-splicing. Both outcomes 1 and 3 would result in full
length CEP290 peptide. Figure adapted from Dooley, et al., 2018
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Based on this analysis, I designed an AAV genome encoding the cytomegalovirus (CMV)
promoter driving expression of a 5’ pre-mRNA trans-splicing molecule containing coding
nucleotides 1 through 2,991, which encodes Met1 through Glu997 p.(M1-E997), and added a
cloning site for the addition of a binding domain (Figure 2.5).
CEP290 5’ pre-mRNA trans-splicing molecule (PTM)
5’

ITR

CMV

5’ PCDS
c.1 through 2991

5’SS

Spacer

Binding Domain
In intron X-27

pA

ITR

3’

Figure 2.5 Illustration of an adeno-associated virus genome encompassing the therapeutically
relevant CEP290 5’ trans-splicing molecule. Inverted terminal repeats (ITR) flank an expression
cassette consisting of the cytomegalovirus promoter (CMV), a partial coding DNA sequence (PCDS)
encoding the first 2,991 nucleotides of the coding DNA sequence, a 5’ splice site (5’ SS), a spacer
region, a binding domain that is reverse complementary to a region of intron X-27, and a
polyadenylation signal sequence (pA). Figure adapted from Dooley, et al., 2018

Screening of binding domains in CEP290 intron 26
The specificity of a PTM is conferred by the binding domain annealing to a target premRNA through Watson-Crick base pairing. To identify a functional binding domain in intron X-27, I
adapted a previously described fluorescence reconstitution assay (Uchida et al., 2017; Wally et al.,
2010). Briefly, the complete coding DNA sequence of the Aequorea coerulescens-derived green
fluorescent protein (GFP) mammalian enhanced (codon optimized) sequence was split between
Glu112 and Val113 (GAG|GTG) (Murauer, Koller, Hainzl, Wally, & Bauer, 2013). To screen binding
domains for a 5’ trans-splicing strategy, the 5’ GFP PCDS (Met1 through Glu112) was cloned into
a 5’ PTM reporter while the 3’ GFP PCDS (Val113 through Stop240) was cloned downstream from
the complete CEP290 target intron 26-27 in a novel mini-gene plasmid. A trans-splicing event
between the pre-mRNAs of the two plasmids would thus reconstitute the GFP open reading frame
and result in GFP positive cells (Figure 2.6).
5’ GFP BD
Test PTM

CMV

5’ GFP

5’SS

Spacer

Binding Domain

polyA
GFP

3’GFP Mini-Gene
Target

Exon 26

3’GFP

polyA

Intron 26-27
3’ SS

Figure 2.6 Schematic of trans-splicing between a reporter and CEP290 intron 26 target molecule.
Illustration of a 5’ binding domain (BD) test pre-mRNA trans-splicing molecule (PTM) encoding the 5’
portion of green fluorescent protein (5’ GFP) and a mini-gene target encoding the 3’ portion of green
fluorescent protein (3’ GFP). Watson-Crick base pairing is indicated by vertical dashed lines. Transsplicing between the two pre-mRNAs results in reconstitution and expression of GFP. Figure adapted from
Dooley, et al., 2018
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To generate a binding domain library, I evaluated the sequence of intron X-27 for frequently
cutting blunt restriction enzymes with consensus sites in the target region (Tockner et al., 2016).
This analysis revealed that a combination of RsaI and DraI was predicted to yield mostly fragments
between 50-300 nucleotides, which has been described as the optimal size for binding domains
(Puttaraju, DiPasquale, Baker, Mitchell, & Garcia-Blanco, 2001) (Figure 2.7, top). I then amplified
intron X-27 from genomic DNA of a healthy-donor and confirmed the presence of expected
fragments after restriction enzyme digestion (Figure 2.7, bottom). The fragment pool was then
cloned into the reporter to generate a plasmid library.
FW R

A

RR

FW R

Exon X

D

RR

01 02

Exon X

04

01 02

03

DR RR R
D

05
04

03

DR

DR RR R
05

07
06

06

07

08

R R

DR

09

10

09

10

08

R

R R

12
12

11

13
13

11

La
dd
er
D
ig
es
t

bp

04

650
500

14

400

15
10

300

12/17

200

05

Size (bp)
120
180
7
708
204
64
147
63
113

c.2991+
1841
1961
2141
2148
2856
3060
3124
3271
3334

Name
10
11
12
13
14
15
16
17

Size (bp)
355
23
264
96
526
386
77
268

c.2991+
3447
3802
3825
4089
4185
4711
5097
5174

RV

15

17

15
16

CEP290 intron X-27 RsaI DraI Predicted Library
Name
01
02
03
04
05
06
07
08
09

RV

R D

14
14

B
1000
850

R D

R

16

17

Exon 27
Exon 27

Figure 2.7 CEP290 Binding
domain library generation. (A)
Diagram of RsaI (R) and DraI
(D) restriction sites within
CEP290 intron X-27. (B) Intron
X-27 was amplified from
genomic DNA, digested with
restriction enzymes RsaI and
DraI, and visualized on a 2%
TBE-Agarose gel. The fragment
library numbers of visible bands
are indicated according to
expected sizes. Figure adapted
from Dooley, et al., 2018

The library and the mini-gene target were transfected alone or co-transfected at an
equimolar ratio into HEK293T cells (ATCC, Manassas, Virginia). GFP-positive wells were
visualized with fluorescence microscopy and assayed at 48 hours after transfection by flow
cytometry to quantify the percentage of GFP positive cells in each population. Co-transfection of
the target with reporter PTMs encoding fragments 02 and 07 resulted in the highest expression of
GFP, while transfection with the reporter PTMs alone resulted in less than 1% GFP-positive cells
(Figure 2.8).

23

Interestingly, the reporter with no binding
Screening of CEP290 intron X-27
Binding Domain Library

domain (NBD) generated a small fraction of GFP
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positive cells when co-transfected with the target.
Reporters with a binding domain sequence in
forward orientation, demarked “f”, were predicted
to not improve trans-splicing efficiency and
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ClustalOmega (Goujon et al., 2010; Sievers et al.,
2011) and BLASTn (National Library of Medicine
(US), n.d.) did not reveal regions of homology
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Figure 2.8 Quantification of a GFP
reconstitution assay for CEP290 intron X-27.
HEK293T transiently transfected with a
fragment library test PTM (grey bars) or cotransfected with a test PTM and the 3’ GFP
target (black bars) were quantified by flow
cytometry for GFP expression. Samples with “f’
demark forward orientation which is not
predicted to confer trans-splicing specificity.
Figure adapted from Dooley, et al., 2018

which would be predicted to facilitate trans-splicing.
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I next wanted to validate that GFP signal was resulting from reconstitution of the GFP open

200

to the junction between the 5’ and 3’

100

portions of GFP to probe cDNA generated

FW
5’GFP

from treated cells. A band of expected size
was

amplified

in

all

samples

co-

transfected with both the target mini-gene
and the reporter molecules but not when
individually transfected (Figure 2.9).
As CEP290 is a ubiquitously

RV
3’GFP

Figure 2.9 Agarose gel electrophoresis confirms
reconstitution of the GFP coding sequence.
Electrophoresis of RT-PCR using cDNA generated from
HEK293T cells transfected with plasmids in 2.8.
Primers were designed to specifically bind to the 5’ or
3’ portions of the GFP coding DNA sequence to validate
trans-splicing between the 5’ Test PTM and the 3’ GFP
target pre-mRNAs. Data for the other test PTMs has
been removed at the break indicated. MG, mini-gene.
Figure adapted from Dooley, et al., 2018

expressed gene, the test molecules were predicted to also trans-splice to endogenous pre-mRNA.
To investigate this, I used the same 5’ GFP primer and paired it with a primer binding to CEP290

24

exon 27. A band was exclusively detected in cDNA from cells that were transfected with BD_07,
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and co-transfection reduced the intensity of this band (Figure 2.10).
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Figure 2.10 Agarose gel electrophoresis confirms transsplicing of 5’ GFP to CEP290. Electrophoresis of RTPCR using cDNA generated from HEK293T cells
transfected with plasmids in 2.8. Primers were designed
to specifically bind to the 5’ portion of GFP or to exon 27
of Homo sapiens CEP290. Image has been contrast
enhanced to visualize the faint band in lane 7 for cotransfection of BD_07 with target mini-gene (MG). Figure
adapted from Dooley, et al., 2018

Editing of endogenous CEP290 transcripts in HEK293T by trans-splicing
Since transfection of HEK293T with the screening plasmid resulted in detectable transsplicing of 5’ GFP to endogenous CEP290, I then cloned the BD_07 sequence into a PTM encoding
the 5’ PCDS of CEP290. The presence of a transcriptional terminator on a PTM has been
demonstrated to have mixed results which may be context dependent (Mearini et al., 2013). Lack
of a terminator is expected to retain a pre-mRNA in the nucleus, which could facilitate the transsplicing reaction. To assess this effect in our system, I generated constructs with a bovine growth
hormone poly-adenylation signal sequence (PTM_07 PA) or no poly-adenylation sequence
(PTM_07 NPA) (Figure 2.11).

PTM_07 NPA 5’

ITR

CMV
Promo

Codon optimized PCDS
c.1 through 2991
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Figure 2.11 Illustration of adeno-associated virus genome arrangement of a CEP290 5’ pre-mRNA
trans-splicing molecule with binding domain 07 (PTM_07) with either no poly-adenylation signal
(NPA) or with a bovine growth hormone poly-adenylation signal (PA). ITR, inverted terminal repeat;
CMV, cytomegalovirus promoter; PCDS, partial coding DNA sequence of CEP290; 5’SS, 5’ splice
site. Figure adapted from Dooley, et al., 2018

To elucidate nuanced differences between treatments, I performed quantitative PCR with
TaqMan probes on cDNA from HEK293T cells transfected with the 5’ PTMs or a GFP plasmid and
RNA was isolated at 72 hours post treatment. Cells treated with PTM_07 PA showed a slight but
insignificant reduction of the CEP290 exon 26-27 junction (Figure 2.12, left). I also designed a
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probe internal to the 5’ codon-optimized sequence that detects overall expression of the 5’ PCDS
regardless of trans-splicing to endogenous pre-mRNA or maturation of the PTM transcript without
trans-splicing. This probe showed a trend toward a 2.5-fold increase in PTM expression for PTM_07
PA when compared to PTM_07 NPA, though it was also not statistically significant across biological
replicates (Figure 2.12, center). Similarly, I observed amplification of trans-spliced products with
treatment by both NPA and PA PTMs with an insignificant 3-fold trend for higher trans-splicing in
the samples with a poly-adenylation signal (Figure 2.12, right).
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Figure 2.12 Quantitative PCR was performed on HEK293T transfected with a plasmid encoding green
fluorescent protein as a transfection control or the plasmids in 2.11. TaqMan probes were designed to
the junctions indicated: (A) CEP290 exons 26 and 27 (hEx26-hEx27), (B) a region within the 5’ codon
optimized partial coding DNA sequence (coPCDS), (C) or the novel junction of 5’ coPCDS and
endogenous Homo sapiens exon 27 to signify trans-splicing (coPCDS-hEx27). Significant variation
within replicates for coPCDS-hEx27 was present because the Ct was crossed at 35 cycles with either
PTM; however, no amplification was observed through 40 cycles in GFP-treated samples. Samples
were standardized to β-2-microglobin and normalized to NPA. Error bars are relative quantity
minimum/maximum at 95% confidence intervals. Figure adapted from Dooley, et al., 2018

As a control, I generated similar PTMs lacking a binding domain. I did not detect transsplicing in cells treated with no binding domain. Finally, I also validated the trans-spliced product
by visualizing the PCR product of the trans-splicing detection reaction and confirmed a band of the
expected size in both PTM_07 NPA and PA treated samples but not untreated or GFP treated
reactions (Figure 2.13, left). The band of PTM_07 PA had a slightly higher density than PTM_07
NPA (Figure 2.13, right).
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Figure 2.13 Visualizing the RT-qPCR trans-spliced product. (A) Agarose gel electrophoresis
of one of the replicate reactions from 2.12 C. (B) Densitometry analysis of the primary band
in (A). Figure adapted from Dooley, et al., 2018

Finally, I further validated the novel splice-junction with Sanger sequencing of both the
qPCR band and a second PCR amplicon derived from end-point PCR with another primer pair.
Analysis of these sequencing
reads confirmed the novel
junction of codon-optimized
exon 26 to endogenous exon
27 with asterisks (*) indicating
nucleotide changes designed
by codon-optimization (Figure

Figure 2.14 Sanger sequencing following TOPO-cloning of the
PCR product comprising the coPCDS-hEx27 junction visualized in
2.13. Nucleotide differences between Homo sapiens and codonoptimized CEP290 are noted by asterisks. The junction between
the 5’ coPCDS and endogenous exon 27 is marked by a vertical
dashed line. Figure adapted from Dooley, et al., 2018

2.14).

Maturation of the PTM is detected at high levels
After observing higher Ct values of codon-optimized sequence expression than transsplicing following transfection, I suspected that PTM genomes could be transcribing and generating
mature mRNA without trans-splicing. I added an amino-terminal HA-tag to PTM_NBD PA and
PTM_07 PA to assess peptide production from the PTMs and added the CMV Enhancer to further
increase expression. In silico sequence analysis of the 5’ PTM revealed an open reading frame
that could generate a predicted peptide of 118.7 kDa (Figure 2.15).
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Figure 2.15 Illustrations of PTM genome open reading frames. In silico analysis of both genomes encoding
either the 5’ pre-mRNA trans-splicing molecule with no binding domain (PTM_NBD) or with CEP290 intron
X-27 binding domain 07 (PTM_07) indicates an open reading frame is present that is predicted to encode
a 118.7 kDa peptide if the pre-mRNA matures without trans-splicing. Figure adapted from Dooley, et al.,
2018

To assess if this peptide was indeed present, I performed western blot analysis of protein
extracts from HEK293T transfected with the HA-tagged PTMs. This revealed an HA-tagged protein
between 110 kDa and 160 kDa with a minor band between 80 and 110 kDa, while no HA-tagged
protein was detected above 260 kDa (Figure 2.16, left). A 290 kDa band would be expected for
trans-splicing to endogenous CEP290. There was neither a significant change to the levels of
CEP290 protein following transfection nor a statistically significant difference in levels of the 118.7
kDa peptide between PTM_NBD and PTM_07 (Figure 2.16, right).
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Figure 2.16 PTM transfection yields a 118.7 kda HA-tagged peptide. (A) Representative western blot
images of HA-tag and CEP290 using extracts from HEK293T harvested 72 hours following transfection
with the indicated plasmids. HA-tagged CEP290 resulting from trans-splicing was expected at ~290
kDa. α-Tubulin was used as a loading control. (B) Densitometry quantification of CEP290 and the 118.7
kDa bands. Values per replicate group were standardized to α-Tubulin and normalized to PTM_NBD.
Error bars are standard deviation, n=6 independent experiments. p < 0.05 was considered significant.
Figure adapted from Dooley, et al., 2018
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The addition of a downstream intronic splice enhancer (DISE) derived from rat FGFR2 has
been demonstrated to promote inclusion of exons and PTMs (Lorain, Peccate, le Hir, & Garcia,
2010; Seth, Miller, Lasda, Pearson, & Garcia-Blanco, 2008). I inserted the corresponding sequence
into the spacer region of PTM_07 and performed transfections in HEK293T. I observed no
significant differences in RNA or protein levels between treatment with PTM_07 or PTM_07 FGFR2
DISE.

Cas9-engineered CEP290 deficient 1D9 cells derived from HEK293T
I next wanted to explore the ability of the CEP290 5’ PTM to rescue CEP290 mRNA in a
deficient model. In collaboration with Devin McDougald, we designed guide RNAs for
Streptococcus pyogenes Cas9 to target

(Figure 2.17, top). Of three putative
guide sequences, we identified one,
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Figure 2.17 Cas9 cleavage
of CEP290 exon 2. (A)
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Illustration
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pyogenes
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(SpCas9) to exon 2 of
CEP290. (B) Surveyor assay
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black arrows.
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mismatch assay (Guschin et al., 2010)
(Figure 2.17, bottom). I then isolated

and screened single cell clones of HEK293T transduced with Cas9 and sgRNA3 for CEP290
protein deficiency. Clones 1D8 and 1D9 had 30% and 10%, respectively, of wild-type CEP290
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260

CEP290

60

α-Tubulin

50

1.0

0.3

0.1

Figure 2.18 CEP290 is reduced in Cas9-treated HEK293T.
Western blot of CEP290 from protein lysates of HEK293T
transduced with lenti-SpCas9 sgRNA3, selected with Puromycin,
and expanded from single cell clones. Quantification by
densitometry analysis with normalization to α-Tubulin reveals the
level of CEP290 protein was 30% of wild-type in clone 1D8 (Lane
3) and 10% of wild-type in clone 1D9 (Lane 4).
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HEK293T-1D9 Genotype with reference to NM_025114.3:
- Allele 1: c.69_72delinsTAATTTATTGATTATCT p.(Glu22fsTer9)

- Allele 2: c.69_77del p.(Glu23_Ala25del)

I next wanted to ask if loss of CEP290 creates a cilia defect in these cells. I performed
immunofluorescence with antibodies against ARL13b, a marker of cilia, and pericentrin, a marker
of ciliary bodies. Clone 1D9 had a 50% reduction in the number of cells with a cilia present in a
cycling population compared to parental HEK293T cells (Figure 2.19).
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Figure 2.19 Immunofluorescence imaging shows reduction of cilia formation in 1D9 cells. (A)
Representative merged image of ARL13b (green), a marker of cilia, pericentrin (red), a marker of ciliary
bodies, and DAPI (blue), a marker of nuclei. White arrows indicate the presence of cilia. (B) Average
quantification of at least 350 cells, error bars represent the standard deviation of 5 images.

Next, I performed Sanger sequencing of CEP290 exon 2 to evaluate the specific mutations
in clones 1D8 and 1D9. This analysis revealed three distinct alleles in clone 1D8 indicating a
polyclonal lineage. I identified only two alleles in clone 1D9, both of which had modifications present
at 2 nucleotides upstream of the Cas9 proximal adjacent motif site (Figure 2.20).

Figure 2.20 Sanger sequencing results of genomic DNA extracted from clone 1D9 and aligned to Homo
sapiens CEP290. Two alleles were detected when genomic PCR fragments were cloned from 1D9
genomic DNA and sequenced: Allele 1 shows a 17-nucleotide insertion in CEP290 exon 2 followed by a
4-nucleotide deletion for a net gain of 13 nucleotides leading to a predicted frame shift with stop codon
after 9 codons. Allele 2 shows a deletion of 9 nucleotides at the same location and results in a predicted
loss of 3 amino acids.
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Allele 1 had an insertion of 17 nucleotides and a deletion of four bases for a net gain of 13
nucleotides. The resulting genotype of this allele was c.69_72delinsTAATTTATTGATTATCT
p.(Glu22fsTer9). Allele 2 had a 9-base deletion. The resulting genotype of this allele was
c.69_77del p.(Glu23_Ala25del). The in-frame deletion of Allele 2 likely accounted for residual
CEP290 protein in the 1D9 cell line. I therefore moved forward with investigating the effects of premRNA trans-splicing on these CEP290-deficient 1D9 cells.

Editing of CEP290 in HEK293T-1D9 cells
In an LCA10 IVS26 homozygous patient-derived fibroblast line, CEP290 protein levels
were found to be approximately 10% of healthy-donor controls, and RNA levels at the exon 26-27
junction were approximately 25% of controls (Parfitt et al., 2016). I therefore expected 1D9 cells to
have at least 50% reduced level of CEP290 transcripts due to nonsense mediated decay of allele
1. I performed pilot transfections with HA-tagged PTMs (Figure 2.21) in HEK293T and 1D9 cells
and harvested RNA at 72 hours post transfection.
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Figure 2.21 Genomes of therapeutic CEP290 trans-splicing molecules. Illustration of adenoassociated virus genome arrangement of a CEP290 5’ pre-mRNA trans-splicing molecule with no
binding domain or binding domain 07 (PTM_07) with a bovine growth hormone poly-adenylation
signal (PA). ITR, inverted terminal repeat; CMV, cytomegalovirus promoter; PCDS, partial coding
DNA sequence of CEP290; 5’SS, 5’ splice site; HA, HA-Tag.

Interestingly, reverse transcription followed by quantitative PCR (RT-qPCR) revealed no
significant difference between 293T and 1D9 in untreated samples at the exon 26-27 junction
(Figure 2.22, left) or at exon junctions 5-6 and 43-44. The junction of native exons 26 and 27 was
unaffected in 293T by any treatment, and this junction was slightly reduced in 1D9 cells at an equal
amount between PTM_NBD and PTM_07 (Figure 2.22, left). Primers specific to an inner region of
the 5’ PCDS would detect total transcription of the PTM regardless of trans-splicing or maturation
of the PTM transcript without trans-splicing. The relative level of PTM_NBD was 50% higher than
PTM_07, and in 1D9 the relative ratio between treatments was similar though the total was
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approximately 50% reduced over 293T (Figure 2.22, center). A probe to detect the trans-splicing
event between the codon-optimized PCDS and native CEP290 exon 27 detected the novel junction
in samples treated with PTM_07 but not with PTM_NBD or untreated, and similarly the relative
amounts were approximately 50% lower in 1D9 than in 293T (Figure 2.22, right). Unfortunately,
even with mRNA editing, no protein rescue or cilia defect correction was detected following
transfection of the trans-splicing construct.
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2.11. TaqMan probes were designed to the junctions indicated: (A) CEP290 exons 26 and 27 (hEx26hEx27), (B) a region within the 5’ codon optimized partial coding DNA sequence (coPCDS), (C) or the
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Evaluating trans-splicing in a murine mini-gene model of hCEP290 intron 26-27
To demonstrate in vivo proof-of-concept pre-mRNA editing of this region of CEP290, I
utilized an engineered mouse model (Bennicelli, Vassireddy, & Bennett, 2012). This model contains
an LCA10 mini-gene driven by the murine sequence immediately upstream to the Rhodopsin gene
and encodes the genomic region of Homo sapiens CEP290 exons 25, 26, intron 26 carrying the
IVS26 mutation, and exon 27. Additionally, a 5’ Myc tag and a 3’ 3xFLAG tag are in-frame with the
CEP290 coding sequences. The cassette is followed by an internal ribosomal entry site and green
fluorescent protein coding sequence (Figure 2.23).

mRho

Myc

Exon 25

Exon 26

Intron 26-27

Exon 27

FLAG
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Figure 2.23 Diagram of the CEP290 intron 26 mini-gene. The mini-gene is driven by the murine
Rhodopsin promoter (mRho). CEP290 exons 25 and 26 are joined and followed by the complete intron
26-27 and exon 27. An A>G mutation corresponding to c.2991+1655 was included to assess exon X
splicing in the model. An amino-terminal Myc and a carboxy-terminal FLAG tag were added to flank the
mini-gene. Additionally, an internal ribosomal entry site (IRES) was added to drive expression of green
fluorescent protein (GFP) and is terminated by a bovine growth hormone poly-adenylation signal
sequence (pA). Figure adapted from Dooley, et al., 2018

32

The Rhodopsin promoter selection should limit expression of the mini-gene to rod
photoreceptor cells. I confirmed that expression of GFP was restricted to photoreceptors in the
outer nuclear layer and the transition zone between the outer nuclear layer and outer segments
(Figure 2.24). Therefore, a detected trans-splicing event can be presumed to be the product of
activity in photoreceptors, even in samples that may contain material from other cell types.
GFP
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Cone Arrestin

DAPI

Composite
OS
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INL

Figure 2.24 Immunofluorescence staining of a retinal cross-section from a mini-CEP290 mouse.
OS, outer segment. ONL, outer nuclear layer. INL, inner nuclear layer. Figure adapted from
Dooley, et al., 2018

In this model, normal cis-spliced products are expected to generate a 24.3 kDa peptide
while a trans-spliced product would generate a novel 124.1 kDa FLAG band (Figure 2.25).
Additionally, trans-splicing would be predicted to reduce the amount of 24.3 kDa Myc and FLAG.
Potential mRNA Outcomes of RNA Editing
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Figure 2.25 Illustration of potential splicing outcomes within the mini-CEP290 mouse. Canonical cissplicing would result in a predicted 24.3 kDa peptide. Alternative cis-splicing with exon X would yield a
predicted non-sense media decay transcript encoding a truncated peptide with Myc at 17.1 kDa and no
FLAG translation. Trans-splicing with a 5’ pre-mRNA trans-splicing molecule would replace the aminoterminal Myc and generate a 124.1 kDa peptide with a FLAG tag. Arrow pairs indicate locations of PCR
primers used to detect specific splicing events. Figure adapted from Dooley, et al., 2018

To investigate if RNA editing could occur in vivo, I packaged the proviral PTM genomes in
the AAV7m8 capsid, which has shown efficient transduction in vivo in mouse and primate retinas
as well as in vitro for several cell lines (Dalkara et al., 2013; Ramachandran et al., 2017). In
collaboration with Devin McDougald, we then performed sub-retinal injections of control and
experimental AAVs at post-natal day 15 and harvested whole eyes for either RNA or protein
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analysis 30 days post injection. Treatment with the control AAV7m8-PTM_NBD and the
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protein were not exclusively an artifact of AAV injection, I generated cDNA from additional mice
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Figure 2.27 Densitometry quantification of western blot images of Myc and FLAG at 24.3 kDa from
100
protein extracts of whole eyes of mini-CEP290
mice. Eyes were treated by sub-retinal injection with 5’
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A.U., arbitrary units. Figure adapted from Dooley, et al., 2018

and evaluated transcript levels using TaqMan probes specific to: (1) the Homo sapiens exon 27 –
FLAG junction to gauge expression of all mini-gene transcripts including cis-spliced or transspliced, (2) an internal sequence of the codon-optimized PCDS to gauge expression of all PTM34
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indicating trans-splicing of the codon-optimized PCDS to Homo sapiens exon 27 (Figure 2.25,
arrows). Analysis of samples by biological groups revealed that injection of either PTM_NBD or
PTM_07 reduced overall expression of the mini-gene by approximately 75% (Figure 2.28, left).
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observed in untreated samples (Figure 2.28, center). While there were higher overall levels of
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5’ PCDS was detected with either treatment, but, importantly, levels were 25-fold higher with
PTM_07 (Figure 2.28, right).
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Figure 2.28 Summary quantitative PCR from cDNA generated by RNA extracts from whole eyes of
mini-CEP290 mice. TaqMan probes were designed to the junctions of Homo sapiens exon 27 and FLAG
to detect total expression of the mini-gene (A), to a region within the PCDS to detect total expression of
the PTM (B), or to the novel junction of codon-optimized CEP290 PCDS and Homo sapiens CEP290
exon 27 (C). Values from treatment-matched samples were averaged as biological groups,
standardized to murine β-2-microglobin and normalized to PTM_NBD. p < 0.05 was considered
significant. Error bars are relative quantity minimum/maximum at 95% confidence intervals. Sample
sizes as indicated. Figure adapted from Dooley, et al., 2018

Individual data grouped by contralateral eye treatments demonstrates variability between
mice but shows consistently that trans-spliced products are detected at higher levels after treatment
with PTM_07 relative to PTM_NBD, and in 5 out of 27 untreated eyes some level of trans-splicing
was detected but at amounts resembling PTM_NBD (Figure 2.29). One animal that was injected
with PTM_07 had no visible bleb after injection. Interestingly, in this sample, the level of codonoptimized PCDS was reduced, and trans-splicing was not detected (Figure 2.29, animal 26). This
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sample provided evidence that successful sub-retinal injection of AAV7m8 PTM vectors is required
to mediate trans-splicing activity to a photoreceptor-specific target.
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Figure 2.29 Individual quantitative PCR from cDNA generated by RNA extracts from whole eyes of
mini-CEP290 mice. TaqMan probes were designed to the junctions of Homo sapiens exon 27 and
FLAG to detect total expression of the mini-gene (top), to a region within the PCDS to detect total
expression of the PTM (center), or to the novel junction of codon-optimized CEP290 PCDS and Homo
sapiens CEP290 exon 27 (bottom). Injection of animal 26 with PTM_07, indicated by asterisk (*) did
not yield a visible bleb and concurrently no trans-splicing was detected in this sample. Samples are
grouped by contralateral eye treatments per animal and treatment cohorts are separated by vertical
dashed lines. Ct values were standardized to the β-2-microglobin control gene to generate ΔCt values.
A.U., arbitrary units. Figure adapted from Dooley, et al., 2018
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Discussion
Pre-mRNA trans-spicing can successfully edit CEP290 mRNA
Gene augmentation and editing strategies for targets with a coding sequence greater than
4,000 nucleotides face many challenges. The size of delivery vectors imposes a restriction on which
targets can be utilized in canonical gene augmentation. In this chapter, I have shown that
spliceosome mediated pre-mRNA trans-splicing can be utilized to edit transcripts of CEP290.
Mutations in CEP290 cause severe early onset blindness (LCA10), which can also be accompanied
by systemic disease. Here, I showed that I could target a PTM downstream of cryptic exon X both
in vitro and in vivo and observe mRNA trans-splicing. This approach could ultimately correct at
least one allele in nearly 70% of LCA10 patients and approximately 50% of all reported loci with
mutations within CEP290. Many studies have also shown that 3’ PTMs can replace the 3’ region of
genes. By applying our analysis paradigm in the reverse direction, one can also calculate a maximal
3’ PCDS size (Table 2.1). Through the two approaches, nearly 90% of reported CEP290 mutation
loci can hypothetically be targeted.
Through this work I have created an analysis paradigm that can be applied to any gene
target to maximize potential benefit. Our low-throughput screen identified two candidate-binding
domains that could reconstitute GFP. High-throughput screens have been utilized in a variety of
other studies by applying techniques including sonication to generate robust libraries (Gruber et
al., 2013; Monjaret et al., 2014; Murauer et al., 2013; Trochet et al., 2016; Wally et al., 2010).
Regardless of screening method, efficiency of trans-splicing continues to be the rate-limiting step
for efficacy. Indeed, in another study, repair of Rho showed in vivo trans-splicing and protein
production after sub-retinal injection but did not demonstrate phenotypic rescue (Berger et al.,
2015). In this study, animals were not injected until postnatal day 21, while the onset of Rho
expression is around postnatal day 5 with aberrant localization evident by day 7 (Bowes, van Veen,
& Farber, 1988). After factoring the duration for onset of transgene expression after injection, it is
possible that the animal eyes had degenerated beyond feasible rescue. Ongoing studies will
hopefully identify what properties influence binding domain characteristics and trans-splicing
efficiency. There may be additional features which affect efficiency of trans-splicing, such as the
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efficiency of splicing in the native molecule (Philippi et al., 2015). Further refinements to the
components of the pre-mRNA trans-splicing molecules will ideally allow for optimization of the
analysis parameters and improve trans-splicing efficiency (see Chapter 5 Discussion).

Untargeted affinity for trans-splicing
Unexpectedly, our negative control of the untargeted PTM with no binding domain did
reconstitute the open reading frame in our GFP screen. Additionally, three of the GFP-positive
library clones had binding domain fragments in forward orientation which were not expected to
confer specificity of the PTM (05f, 09f, 13f), yet these samples had GFP detected at low levels.
Since the levels of the forward binding domain clones were not significantly higher than the no
binding domain sample, the observation may be the result of non-specific, random trans-splicing
resulting from an abundance of transcription template following transfection. Transcripts resulting
from expression of transfected plasmids may be compartmentalized such that there is an increase
in the local concentrations of the two molecules sufficient for stochastic trans-splicing. Further
studies including in situ hybridization will help identify the cause of this untargeted trans-splicing.
Specificity of the trans-splicing reaction to endogenous transcript conferred by the binding
domain was confirmed by comparing transfection of BD_07 alone or BD_07 co-transfected with the
mini-gene. Reduction in the trans-spliced 5’ GFP – exon 27 product when co-transfected with the
target mini-gene reflects specificity of the binding domain since overexpression of the target minigene would create additional target sites for the PTM transcripts.

Maturation of trans-splicing products
Regarding the transcriptional terminator, my findings suggest that the poly-adenylation
signal sequence increased PTM expression and that this correlated with higher trans-splicing, albeit
not statistically significant. The basis for removal of the transcriptional terminator was to prevent
maturation of the pre-mRNA and promote nuclear retention since the molecule would lack the
elements required for nuclear export. Increasing hnRNP binding sites may be another option for
preventing export from nucleus. However, I cannot rule out other variables such as RNA structure
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that may be independent of the poly-adenylation tail and a result of changes to the overall PTM
genome. Indeed, PTMs targeting murine dystrophin were improved with an intronic splice enhancer
sequence (Lorain et al., 2010). Addition of this particular enhancer did not improve trans-splicing
in our system, but there may be alternative sequences that can improve spliceosome recruitment
in this context. A thorough analysis of additional transcriptional terminators and other intron binding
elements on trans-splicing molecules may help reveal copy number, RNA-structure, and other
context-dependent effects that can contribute to future optimizations.
By probing for the HA-tag on our 5’ codon-optimized CEP290 PTM, I discovered that
translation of the PTM occurred with a peptide at the size predicted by an open reading frame
present in the PTM genome. This open reading frame is only present if the 5’ splice site does not
prevent maturation of the pre-mRNA. With BD_07 present, in silico analysis revealed multiple
putative stop codons for the open reading frame. Mutation of the PTM genome to remove these
putative stop codons would require changes to not only the spacer but also within the binding
domain, which may reduce specificity and binding efficiency. Alternative transcriptional terminators
and additional nuclear retention elements may be required to reduce this cis-splicing and increase
the retention of PTM pre-mRNA, which, per the earlier poly-adenylation signal hypothesis, could
increase trans-splicing availability.

Modeling trans-spicing in vivo using mouse models
Mini-gene systems have been used to dissect alternative splicing in a variety of models
(Cooper, 2005). When the Homo sapiens CEP290 exon 26, intron 26 with IVS26, and exon 27
region was targeted for specific insertion into the homologous region in a mouse, an mRNA species
was identified which retained a second cryptic exon, dubbed exon Y, which is not observed in any
human cDNA samples (Garanto et al., 2013). This finding suggested that splicing in the mouse
may not accurately recapitulate human splicing as a model of IVS26.
I thus investigated the utility of a tagged mini-gene containing only the region of interest
when expressed in mouse photoreceptors. Variability in both baseline levels of mini-gene and in
expression of transduced 5’ PTMs was observed between mice and is potentially due to biological
39

and/or injection variability resulting in dose variations. However, dose variation alone would not
account for the 25-fold overall difference seen for PTM_07 trans-splicing as a group, or the
consistently higher levels of trans-splicing in individual animals treated with PTM_07 compared to
the contralateral eye treated with PTM_NBD. With Ct values after 35 cycles, the PTM_NBD signal
is likely the result of rare un-targeted trans-splicing events. These same events were observed in
the initial screen when using the 5’ GFP with no binding domain. Additionally, five untreated
samples from Cohort C had slight amplification with a mean value significantly less than that of
PTM_NBD, which may indicate that the primer-probe set is not perfectly specific or there may be
low amounts of vector trafficking between eyes as no signal was detected in any samples of Cohort
A, which had both eyes untreated. I also validated the PCR products to ensure that the observed
signal was not a result of secondary sources such as primer dimers or non-specific amplification
within the sample. Non-specific trans-splicing may be resolved by improved engineering of the
trans-splicing molecules and will be important to consider in future safety studies of trans-splicing.
Efficiency of trans-splicing molecules may also be context specific. Our mouse model
maintained a higher genomic copy number of the mini-gene, which may be contributing to
increased pre-mRNA expression and trans-splicing. As with any model, there may be also be
differences that vary between species that can alter the outcome of experiments. When using
models to study splicing, it is important to consider that the influence of splicing factors varies
between the retina and other cell types. Mutations in the splicing factor genes PRPF3, PRPF8 and
PRPF31 cause autosomal dominant retinitis pigmentosa but rarely manifest other disease
(Tanackovic et al., 2011). It will therefore be important to evaluate trans-splicing in additional
models including patient-derived samples and ideally photoreceptor cells or retinal explants and to
be mindful of how well the model can be expected to recapitulate in vivo physiology. Regarding
LCA10, patient derived induced pluripotent stem cells have been shown to have lower levels of
CEP290 transcripts (Shimada et al., 2017). Evaluating trans-splicing in these models, including
nuclear fractionation to detect pre-mRNA, will help reveal if pre-mRNA is present in sufficient
quantities to facilitate trans-splicing.
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Conclusion
Collectively, I have demonstrated that 5’ pre-mRNA trans-splicing can be targeted to edit
CEP290 transcripts. This establishes an approach that can be further optimized to correct a broad
range of patient mutations in the region 5’ to and including IVS26. Contrary to other methods of
treatment, this approach creates the opportunity to correct both IVS26 and other alleles. The
approach can ultimately be expanded to other monogenic ocular and extra-ocular diseases
associated genes that are too large to fit in adeno-associated virus.
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Materials and Methods
In silico analysis
Nucleic acid sequences were analyzed and Sanger sequencing alignments were
performed with SnapGene software (GSL Biotech, Chicago, Illinois). Analysis of real-time PCR
results was performed with ExpressionSuite Software v1.1 (Applied Biosystems). Graphs and
statistical calculations were generated with GraphPad Prism v7 (GraphPad Software, La Jolla,
California). Densitometry analysis of immunoblot images was performed with ImageJ software
(https://fiji.sc). Computation of densitometry values was performed using Microsoft Excel.

Statistics
Densitometry measurements of western blots were standardized to sample-matched αTubulin values. For HA-tagged PTM experiments, six independent transfections were performed
and protein lysates were evaluated by immunoblotting. Densitometry values were normalized to
PTM_NBD treated lanes. Adjusted densitometry values of peptides of interest were compared in
Graphpad Prism software using one-way ANOVA followed by Tukey’s multiple comparison test. A
p-value less than 0.05 was considered statistically significant.
Ct values of TaqMan PCR were standardized to the β-2-microglobin control gene. Samples
with matching treatments were considered biological groups and mean ΔCt values were computed
per group. All reactions were performed in technical triplicates for each biological replicate and
processed with the ΔΔCt method. Values were normalized to PTM_NPA or PTM_NBD as
appropriate. The means of biological groups were compared via student’s t test with confidence
intervals calculated at 95%. A p-value less than 0.05 was considered statistically significant.
A post-hoc power analysis was conducted for the trans-splicing Ct values of the in vivo
studies with a 2-sample 1-sided test. With an alpha of 0.05, the power was greater than 0.999 when
comparing cohorts and the study included more than the minimal number of samples for
significance.
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Culture conditions and transfection of HEK293T
HEK293T were maintained in DMEM with GlutaMax (Thermo Fisher Scientific, Walham,
Massachusetts) supplemented with 10% v/v fetal bovine serum (GE Healthcare, Little Chalfont,
United Kingdom) and 100 U/mL Pen Strep (Thermo Fisher Scientific). Dissociation of cells was
achieved by washing with DPBS (Corning, Corning, New York) and incubation with Trypsin-EDTA
0.05% v/v (Thermo Fisher Scientific).
All transfections were performed with Lipofectamine LTX (Thermo Fisher Scientific) per
manufacturer’s instructions at a 3:1 ratio of reagent to plasmid. For binding domain screening, 5 x
104 cells were plated in 24-well cluster plates. 1 µg of library clone plasmid was transfected either
alone or with equimolar Target plasmid along with an equal volume per weight of PLUS reagent.
For protein extracts, 3 x 105 cells were plated in 6-well cluster plates and transfected with 2.5 µg
plasmid with an equal volume per weight of PLUS reagent. At harvest, 10% of dissociated cells
were separated for RNA and 90% for protein.

cDNA preparation and RT-qPCR
RNA was isolated from whole mouse eyes following euthanasia and enucleation. Eyes
were stored in 500 µL of RNAlater™ (Thermo Fisher Scientific) and homogenized by electric pestle
in 350 µL Buffer RLT Plus. RNA was isolated from cell pellets or homogenized eyes with the
RNeasy Plus Kit (Qiagen, Germantown, Maryland) per manufacturer’s instructions following
homogenization through QIAshredder columns (Qiagen). Total RNA concentration was quantified
on NanoDrop™ 8000 spectrophotometer (Thermo Fisher Scientific). Reverse transcription was
performed with Superscript III 1st Strand Synthesis (Thermo Fisher Scientific). Quantitative PCR
was performed with TaqMan™ Fast Universal PCR Master Mix (Applied Biosystems, Foster City,
California) with cycling performed in an Applied Biosystems® 7500 Fast Real-Time PCR system.
Stock primer-probes included human and murine β-2-microglobin (Thermo Fisher Scientific).
Custom primer-probes were ordered from Thermo Fisher Scientific for: codon-optimized PCDS
internal FW 5’-ACC AAG GAA ATC AAT AAG CTG GAA CT-3’, RV 5’-GAT CAT TGT TTT GGG
TTC CAG TCC TA-3’, probe 5’-CAG GGC TTC GTT CTC ATC G-3’; or CEP290 exon 27 – FLAG
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FW 5’-ACT ATT GAA CAA GCC TGG GAA CAG-3’, RV 5’-TCA TCC TTG TAA TCG ATG TCA
TGA TCT TT-3’, probe 5’-TTT GTA GTC CCC TAA TTT AG-3’. The codon-optimized exon 26 to
endogenous exon 27 for detection of trans-splicing was ordered from Integrated DNA
Technologies: FW 5’-GTT GGT CCA GAG GAC TTC AAA-3’, RV 5’-TAT TGA ACA AGC CTG GGA
ACA-3’, probe 5’-TCT TGA GCA CTT GGA GTG TGA AA-3’.

Protein extraction
Protein extracts were isolated from either cell pellets or whole eyes by lysis buffer
consisting of Radioimmunoprecipitation assay (RIPA) Buffer (Cell Signaling Technologies,
Danvers, Massachusetts) supplemented with cOmplete™ proteasome inhibitor (Roche, Basel,
Switzerland). Following euthanasia and enucleation, whole eyes were homogenized in 250 µL of
RIPA Buffer by electric pestle. Cell pellets were re-suspended in RIPA at a 1:1 volume to the cell
pellet. Cell or eye lysis solutions were vortexed for 30 seconds, rotated end-over-end for 30 minutes
at 4°C, vortexed for 30 seconds, centrifuged at 21,000 x g for 20 minutes at 4°C, and proteincontaining supernatant was harvested. Quantification of protein concentration was performed with
Micro BCA™ Protein Assay Kit (Thermo Fisher Scientific).

Western blotting
Protein samples were separated via the NuPage® Electrophoresis System (Thermo Fisher
Scientific) per manufacturer’s instructions. Samples were heated at 70°C for 10 minutes and loaded
to NuPAGE® 3-8% Tris-Acetate (Figure 4) or NuPage® 4-12% Bis-Tris (Figure 5, S1) Protein Gels
(Thermo Fisher Scientific). Novex® Sharp Pre-stained Protein Standards (Thermo Fisher
Scientific) was used to mark protein band sizes. Separated proteins were then transferred in an
XCell II® Blot Module (Thermo Fisher Scientific) to Immun-Blot® polyvinylidene difluoride
membranes for Protein Blotting (Bio-Rad, Hercules, California) at 30V for 1. After transfer,
membranes were incubated in Tris-buffered saline with 0.1% v/v Tween-20 (Bio-Rad)
supplemented with 5% w/v non-fat dry milk (LabScientific, Highlands, New Jersey) for 1 hour at
room temperature. Primary antibodies and respective dilutions included: rabbit polyclonal anti44

CEP290 (Abcam, Cambridge, Massachusetts) 1:1,000; mouse mAb anti-Tubulin DM1A (Cell
Signaling Technologies) 1:1,000; mouse mAb β-Actin 8H10D10 (Cell Signaling Technologies)
1:2,000; rabbit mAb HA-Tag C29F4 (Cell Signaling Technologies) 1:500, mouse mAb Myc-Tag
9B11 (Cell Signaling Technologies) 1:500; mouse mAb FLAG M2 (Sigma-Aldrich, St. Louis,
Missouri). Primary antibodies were diluted in TBST-5% milk and incubated with respective
membrane portions at 4°C overnight. Membranes were washed 3 x 15 minutes in TBST. Secondary
antibodies anti-mouse HRP ECL (GE Healthcare) 1:10,000 or anti-rabbit HRP ECL (GE
Healthcare) 1:10,000 were diluted in TBST-5% milk and incubated with membranes for 1 hour at
room temperature. Membranes were washed then incubated with ECL2 (Thermo Fisher Scientific)
per manufacturer’s instructions for 5 minutes. Membranes were imaged with an Amersham Imager
600 (GE Healthcare) with chemiluminescence settings.

Generation of PTM binding domain reporter library
Aequorea coerulescens green fluorescent protein (AcGFP) 5’ binding domain reporter
plasmid was a gift from Lloyd Mitchell (Retrotherapy, Bethesda, Maryland). The 5’ GFP reporter
consists of a 5’ GFP portion encoding Met1 through Glu112 and is followed by a canonical GTAAG
5’ splice site, a 20-nucleotide spacer sequence, and a multiple cloning site. The reporter vector was
digested with the blunt cutting endonuclease EcoRV and dephosphorylated with recombinant
Shrimp Alkaline Phosphatase (New England Biolabs, Ipswich, Massachusetts). The treated
reporter was separated by size-exclusion on TBE-agarose gel electrophoresis and a band of
expected size was excised from the gel and column purified with NucleoSpin Gel and PCR Cleanup
Kit (Macherey-Nagel, Bethlehem, PA).
A 4,000-nucleotide target region of CEP290 intron X-27 was amplified from genomic DNA
of a healthy-donor by PCR using Q5 Hot Start High-Fidelity 2X Master mix (New England Biolabs).
Primers were designed to be offset from the splice sites of exon X and exon 27: I26 FW 4kb 5’CCA GGA TGG TGT CGA TCT CC–3’ and I26 RV 4kb 5’-TCT TCT AAT TCC GGC CAC CA-3’.
Reactions were separated by size-exclusion on TBE-agarose gel by electrophoresis and a band of
expected size was excised from the gel. Gel pieces were then column purified using NucleoSpin.
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The purified fragment was digested with the blunt-end generating restriction enzymes DraI and
RsaI in CutSmart Buffer (New England Biolabs) at 37°C for 2 hours then column purified with
NucleoSpin.
A heterogeneous pool of the digested target region was ligated to the blunt-digested
reporter using T4 Ligase (New England Biolabs) with an overnight incubation at 16°C. The ligation
reaction was transformed into Top10 competent E. coli (Thermo Fisher Scientific) per
manufacturer’s instructions. Transformed cells were spread on LB-Agar plates containing 100
µg/mL Ampicillin. Plates were inverted and incubated overnight at 37°C. Clones were screened by
colony PCR to identify insert size with the primers acGFP FW2 5’-ATC ACA TGA AGC AGC ACG
AC 3’ and V5Tag-RVSeq 5’-GGA GAG GGT TAG GGA TAG GC-3’. Cultures of unique clones were
grown and later Sanger sequence verified to generate the binding domain library.

Generation of reporter target mini-gene
A 3’ AcGFP trans-splicing target mini-gene was designed encoding human CEP290 exons
25 and 26, intron 26, and the 3' portion of AcGFP to complete the coding DNA sequence of the 5’
GFP reporter. This mini-gene was generated by in-fusion cloning (Macherey-Nagel) to create a
proviral lenti-plasmid with CMV immediate early promoter, CMV enhancer, Kozak consensus
sequence, ATG start codon, CEP290 exon 26 and intron 26, the 3' portion of GFP, a STOP codon,
and the bovine growth hormone poly-adenylation signal sequence.
To generate a positive control for full length GFP, the 5’ GFP and 3’ GFP sequences were
assembled via in-fusion cloning using the respective 5’ and 3’ PTMs as templates. The fragments
were inserted into an expression plasmid driven by the CMV immediate early enhancer and
promoter.

Screening of binding domains
Library screening was performed by co-transfection of PTM Target 3’ GFP and reporter
PTM binding domain library clones into HEK293T at an equal molar ratio. At 48 hours posttransfection, cells were dissociated, and the fraction of GFP positive cells was determined by flow
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cytometry using BD Accuri C6 (BD Biosciences, San Jose, California). Samples were gated using
a GFP plasmid transfection in which 99.9% of cells were GFP positive.
Confirmation of trans-spliced RNA was evaluated by reverse transcription followed by PCR
using the primers GFP FW1 5’-TTC GAG GAT GAC GGC AAC TA-3’ and GFP RVseq 5’-GCC
ATC CTC CTT GAA ATC GG-3’. Library clones that showed the highest GFP were assessed for
trans-splicing to endogenous CEP290 with primers: GFP FW1 5’-TTC GAG GAT GAC GGC AAC
TA-3’ and hCEP290 E27 RVseq 5’- CCC AGG CTT GTT CAA TAG TGT-3’.

Generation of CEP290 5’ PTM
PCR was utilized to amplify the 5’ partial coding DNA sequence from a codon-optimized
human CEP290 CDS (DNA 2.0 now ATUM, Newark, California) and a 5’ splice site and the first 20
nucleic acids of hCEP290 intron 26 were added via the oligonucleotide primers. This fragment was
cloned into the ScaI site of the AAV proviral vector p1107 (Bennett Lab, Philadelphia, Pennsylvania)
to generate PTM_NBD. PTM_07 was generated by amplifying the binding domain 07 sequence
from the 5’ GFP clone BD15 and inserting this fragment into the EcoRV site of PTM_NBD. All
constructs were validated by Sanger sequencing.

Generation of CEP290-deficient HEK293T by genome editing with SpCas9
We utilized the pLenti-CRISPRv2 plasmid which is a lenti-proviral plasmid that also
contains the U6 promoter to drive expression of a guide-RNA. lentiCRISPR v2 was a gift from Feng
Zhang (Addgene plasmid #52961) (Sanjana, Shalem, & Zhang, 2014). Putative guide RNAs were
designed against the sequence of Homo sapiens CEP290 exon 2 using the CRISPR Design Tool
(http://crispr.mit.edu). Oligonucleotides for the putative guide sequences were synthesized and
inserted into the BsmBI site of pLenti-CRISPRv2 (Sanjana et al., 2014). Lentiviral particles were
produced by triple transfection of pLenti-CRISPRv2-sgRNA3, pSPAX2, and pMD2.G in HEK293T
cells. Cell media was harvested at 48 and 72 hours, pooled, centrifuged at 1,000 x g for 10 minutes,
and viral-supernatant was aliquoted and snap-frozen.
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Transduction of target cells with lentiviral particles was achieved by adding 1 mL of viralsupernatant to complete media of HEK293T cells in a 100 mm culture dish. Media was changed at
24 hours. At 48 hours, Puromycin was added at a final concentration of 1 µg/mL. Genomic DNA
was isolated from treated cells after two passages under Puromycin selection. Detection of editing
of genomic DNA was performed with the Surveyor® Mutation Detection Kit (Integrated DNA
Technologies,

Coralville,

Iowa)
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per

5’-GTT

manufacture’s
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SpCas9_hCEP290_SURFREV 5’-CCT TCA TTA GTG ACT GAG TAA-3’.
Cells treated with lenti-sgRNA3 were then serial diluted to achieve single cell clones. We
determined bi-allelic mutated sequences by generating plasmid clones of PCR amplicons from
genomic DNA with primers C290 Ex2 sgRNA3 test 5’-AGG TGG AGC ACA GTG AAA GAA-3’ and
C290 Ex4 sgRNA3 test RV 5’-AAG CCA GCT CCA CTT CTT GA-3’. Amplicons were cloned into
the pCR-BluntII-TOPO® vector (Thermo Fisher Scientific) per manufacturer’s recommendations
and sequenced with M13 FW 5′-TGT AAA ACG ACG GCC AGT-3′ and M13 RV 5′-CAG GAA ACA
GCT ATG ACC-3′.

Immunofluorescence microscopy
Whole eyes were isolated by enucleation of euthanized animals. Eyes were fixed in 4%
paraformaldehyde for 2 hours on ice and then cryoprotected with 30% w/v sucrose in DPBS. Eyes
were then embedded in Tissue-Tek optical cutting temperature cryopreservation media (Sakura
Finetek USA, Torrance, California) and frozen at -80°C. Embedded eyes were sectioned on a Leica
CM1850 cryostat (Leica Biosystems, Buffalo Grove, Illinois) at 12 µM thickness and transferred to
charged glass microscope slides (Globe Scientific, Paramus, New Jersey). Tissue slices were then
incubated for 1 hour at room temperature in blocking buffer comprised of 10% v/v goat serum
(Sigma-Aldrich) and 0.5% v/v Triton X-100 (Roche) in DPBS (Corning). Primary antibodies of
Rhodamine labeled Peanut Agglutinin (Vector Laboratories, Burlingame, California) 1:100 and
Cone Arrestin (Abcam) 1:100 were diluted in blocking buffer and applied to samples in a humidified
chamber and incubated for 4 hours at room temperature. Slides were then washed three times for
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5 minutes per wash in PBST comprised of 0.5% v/v Triton X-100 in DPBS. Secondary antibody
goat anti-rabbit Cy5 (SeraCare, Milford, Massachusetts) was diluted in blocking buffer 1:100 and
applied to cells for 1 hour at room temperature followed by three washes in PBST and a final wash
in DPBS. Fluoromount-G mounting media (Thermo Fisher Scientific) supplemented with DAPI was
added to slides prior to the addition of No. 1 ½ cover glass (Corning) and sealed with nail polish
(Electron Microscopy Sciences).
10 Z-slices of 1 µM depth were obtained with a FLUOVIEW FV1000 confocal laser
scanning microscope with a PLAPON 60X Oil NA:1.42 objective (Olympus, Center Valley,
Pennsylvania). Images were excited with lasers at wavelengths 405, 488, and 559 or 405 and 635
nm. Z-stacks between images were aligned with FIJI software using Split Channels, then the 635
nm channel was combined with the other three channels using Merge Channels. The composite
image was then flattened using Z Project with Standard Deviation. The final image was rotated and
cropped for display orientation.
For HEK293T and 1D9, cells were plated on glass coverslips pre-treated with poly-L-lysine
solution 0.1% w/v in H2O (Sigma P8920). Cells were fixed with 4% v/v paraformaldehyde (Electron
Microscopy Services 15710) in Dulbecco's Phosphate-Buffered Saline (DPBS) (Mediatech 21-031)
for 10 minutes on ice, washed thrice with PBST comprised of DPBS supplemented with 0.1% v/v
Tween20 (BioRad 1706531). Cells were permeabilized with DPBS supplemented with 1% v/v Triton
X-100 (Roche 10789704001) for 5 minutes on ice, washed thrice, and blocked in PBST
supplemented with 5% w/v bovine serum albumin (Invitrogen 15561020) for 1 hour. Pericentrin
(Abcam AB28144) 1:500 and ARL13β (Proteintech 17711-1-AP) 1:500 primary antibodies were
diluted in blocking buffer and coverslips were incubated for 4 hours at room temperature in a
humidified chamber. Coverslips were then washed thrice with PBST and secondary antibodies
Goat anti-mouse AlexaFluor594 (Life Sciences A11005) and Goat anti-rabbit AlexaFluor488 (Life
Sciences A11008) were diluted in blocking buffer and applied for 1 hour at room temperature.
Coverslips were washed thrice in PBST followed by once in PBS. Fluoromount-G mounting media
(SouthernBiotech 0100-01) supplemented with DAPI was added to slides prior to flipping the
coverslips. The slides were sealed with nail polish (Electron Microscopy Systems 72180).
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Fluorescence micrographs were acquired on an Axio Imager.M2 with an EC Plan-Neofluar
40x/0.75 M27 objective with the AxioCamMR3 camera. Micrographs were analyzed with ImageJ.
The number of nuclei was determined by counting DAPI and the number of cilia was counted as
bright staining for ARL13β co-localized with Pericentrin. The percent of cells with ARL13 β positivity
were counted per field. The average of at least 5 fields per cell line was counted for a total of 451
293T and 356 1D9 cells. The mean percent cilia positive cells per field determined standard
deviation.

Adeno-associated virus vector production
Vectors were produced by the Center for Advanced Retinal and Ophthalmic Therapeutics
Retinal Research Vector Core (Philadelphia, Pennsylvania). Viral lots were: AAV7m8 p628 9.75e12
vg/mL CT-117, AAV7m8 CMVie coC290 PTM NBD 8.86e12 vg/mL CT-332, AAV7m8 CMVie
coC290 PTM BD15 7.45e12 vg/mL CT-333.

In vivo studies
Animals were housed and maintained in accordance with the Association for Research in
Vision and Ophthalmology’s Statement for the Use of Animals in Ophthalmic and Visual Research
and Institutional Animal Care and Usage Committee approval (IACUC #805890). The mini-CEP290
mouse line was generated by pronuclear injection of B6AF1 zygotes with a CEP290 intron 26 minigene driven by the 3.8 Kb murine rhodopsin upstream sequence. The mini-CEP290 mouse line
#406 was generated and maintained by brother-sister matings. Sub-retinal injections were
performed as previously described (Yu et al., 2017). Each retina received 8 x 109 vector genomes
in a volume of 1 µL phosphate-buffered saline supplemented with Pluronic F-68 NF Prill Poloxamer
188.
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CHAPTER 3 Designing a strategy to edit ABCA4

Introduction
Stargardt disease
Stargardt disease is the most prevalent form of juvenile macular degeneration with a
prevalence of 1 in 8,000 (Allikmets et al., 1997). Alternatively known as “Bull’s eye” macular
dystrophy, this disease is characterized by the loss of central vision with retention of peripheral
fields and yellow flecks over the fundus (Rózanowska & Sarna, 2005). Later stages of the disease
result in atrophy of the macula. Because of this, correction of central visual acuity is not possible.
Symptoms typically present early in life and are extensive by adolescence (Tanna, Strauss,
Fujinami, & Michaelides, 2017).
There are three sub-types of Stargardt disease that are classified according to confirmed
mutations in specific genes:
•

Stargardt disease 1 (STGD1): OMIM 248200, Gene: ABCA4 (CCDS 6,822bp,
NM_000350.2). Inheritance: Autosomal Recessive

•

Stargardt disease 3 (STGD3): OMIM 600110, Gene: ELOVL4 (CCDS 945bp,
NM_022726.3). Inheritance: Autosomal Dominant

•

Stargardt disease 4 (STGD4), OMIM 603786, Gene: PROM1 (CCDS 2598bp,
NM_006017.2). Inheritance: Autosomal Dominant

STGD1 is the most prevalent sub-type, while STGD3 and STGD4 are substantially less common.
ABCA4 mutations can cause not only autosomal recessive Stargardt disease, but also LCA, conerod dystrophy, retinitis pigmentosa, and age-related macular degeneration. Thus, ABCA4
mutations cause significant disease burden (Allikmets, 2000; Maugeri et al., 2000; Simonelli et al.,
2004). The complete coding DNA sequence (CCDS) of ABCA4 exceeds the packaging capacity of
recombinant adeno-associated virus and disease inheritance is patterned as autosomal recessive.
For these reasons, ABCA4 is a good candidate for pre-mRNA trans-splicing as an approach for
gene therapy (see Chapter 1). However, preclinical studies of gene rescue using any strategy are
hindered by tissue-specific expression of ABCA4 and the lack of a large animal model. Overcoming
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these challenges will, at least in part, require understanding the biological function of wild-type and
aberrant ABCA4 and the development of novel model systems.

Structure and function of ABCA4
ABCA4, also known as ABCR and Rim protein, has four principle lobes separated by
transmembrane domains (Figure 3.1). The two extracellular domains are connected by disulfide
ABCA4Full

bridges and the two intracellular domains
each encompass a nucleotide binding domain
(NBD) (Bungert, Molday, & Molday, 2001;
Tsybovsky,

Orban,

Molday,

Taylor,

&
Extracellular

Palczewski, 2013; Tsybovsky & Palczewski,
Intracellular

2014). The first NBD tightly binds adenosine
diphosphate while the second NBD is an
active

adenosine

triphosphatase

2281
1

(Ahn,

Beharry, Molday, & Molday, 2003; Tsybovsky

Figure 3.1 Illustration of the membranespanning regions of ABCA4.

et al., 2013).
As a member of the ATP-binding cassette family, ABCA4 was predicted to be a membrane
transporter. Studies utilizing protein isolated from bovine retinas identified that ABCA4
preferentially binds to N-retinylidene-phosphatidylethanolamine (NR-PE) (Beharry, Zhong, &
Molday, 2004). Furthermore, ATP hydrolysis leads to a change in ABCA4 protein conformation and
subsequent release of NR-PE. NR-PE is generated when one molecule of all-trans-retinal reacts
with phosphatidylethanolamine in the disk lumen. ABCA4 can then flip NR-PE from the extracellular
(luminal) outer leaflet of the photoreceptor outer segment disks to the intracellular inner leaflet
(cytoplasmic) where all-trans-retinal and PE have a low Kd and dissociate. Retinol dehydrogenase
can then reduce all-trans-retinal to all-trans-retinol (Kolesnikov et al., 2015).
However, in the absence of ABCA4, NR-PE remains in the lumen where a second molecule
of all-trans-retinal can bind and form the bis-retinoid A2E (Sakai, Decatur, Nakanishi, & Eldred,
1996). A2E further forms aggregates in the retinal pigment epithelium (RPE) after those cells
52

phagocytose the disks, leading to lipid globules known as lipofuscin (Feeney-Burns, Berman, &
Rothman, 1980). These globules are present in Stargardt disease; however, the exact
pathogenicity of these aggregates is an active area of research with proposed mechanisms
including toxic levels of reactive oxygen species and a damaging senescence induced inflammatory
phenotype (Wang et al., 2018; Zhu, Wu, Spee, Ryan, & Hinton, 2009).

Challenges of modeling ABCA4
Testing gene correction using pre-mRNA trans-splicing will require a system where human
ABCA4 is expressed. ABCA4 protein was first identified in the rims of outer segment disks within
rod photoreceptor cells, which led to the initial name of Rim protein (Allikmets et al., 1997; Illing,
Molday, & Molday, 1997). In vivo, ABCA4 is commonly reported exclusively in photoreceptors
(Pollock & Callaghan, 2011). However, expression of a 260 kDa protein has also been identified in
a handful of other tissues including epithelial cells of the choroid plexus in rat brain and the inner
root sheath of hair follicles (Bhongsatiern, Ohtsuki, Tachikawa, Hori, & Terasaki, 2005; Haslam et
al., 2015). Despite these reports, no follow-up studies or downstream applications have been
reported for either cell type. Additionally, a 70 kDa variant of ABCA4 was identified in patientderived keratinocytes, and this variant was used to characterize splice mutations observed in
samples derived from Stargardt patients since the exon of interest was contained in this alternative
transcript (Braun et al., 2013; Wiley et al., 2016). However, the authors did not further explore the
nature of this transcript, and I was not able to identify a known alternatively spliced isoform that
corresponds to a protein of this mass.
As an in vivo model, a mouse was developed that specifically floxed the first exon of Abca4,
but these animals only demonstrated delayed dark adaptation and slightly reduced visual function
(Weng et al., 1999). Further characterization showed increases in lipofuscin in the retinal pigment
epithelium (Mata et al., 2001). The phenotype was enhanced to cone-rod dystrophy by crossing
these Abca4-/- mice with another strain lacking retinol dehydrogenase (Rdh8-/-) (Maeda, Golczak,
Maeda, & Palczewski, 2009). This double knockout mouse strain can be used as a model for retinal
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degeneration, but does not mimic a genotype underlying ABCA4-related Stargardt disease and,
importantly, is not humanized.
In vitro, two human retinoblastoma cell lines, both derived from photoreceptors, have been
characterized as expressing ABCA4: Y79 and WERI (McFall, Nagy, Nagle, & McGreevy, 1978;
McFall, Sery, & Makadon, 1977; Reid et al., 1974). In tissue culture settings, Y79 cells grow in
clusters as suspension cells while WERI cells are semi-adherent. Though lysates from these two
cell lines are generally used as a positive control for ABCA4 expression, the images generated for
the Abcam version of a monoclonal anti-ABCA4 3F4 antibody required a 20 minute exposure for
detection (Abcam, n.d.). So while the protein may be present in these lines, the expression level is
quite low.
Induced pluripotent stem cells (iPSC) have opened the way for modeling patient-specific
genetic backgrounds in culture (Takahashi & Yamanaka, 2006). Successful differentiation of iPSC
to a photoreceptor-precursor state has further expanded this modeling option to also include retinal
phenotypes (Tucker et al., 2013). Additionally, photoreceptor precursor cells have been shown to
express ABCA4 (Albert et al., 2018; Sangermano et al., 2016). Per the protocols of these studies,
the challenges associated with using iPSC-derived photoreceptor precursor cells are: (1)
generating an initial iPSC culture takes several months, (2) maintaining the precursor cells in
clumps called organoids is challenging, and (3) generating sufficient quantities of these organoids
for multiple experiments is difficult. Also, organoids are not stable, so a complex study requires
ongoing rounds of differentiation to ensure available samples. Thus, while photoreceptor precursor
cells are appealing since they do express ABCA4, studies that utilize them require a substantial
time commitment and protocol optimization.
Another recently published approach to modeling patient-specific mutations is to generate
a similar mutation in an exogenous setting (Sangermano et al., 2018). To achieve this, a midi-gene
consisting of portions of the ABCA4 gene can be synthetically created to mimic mutations such as
splice site variants. Transduction and expression of these midi-genes in HEK293T cells can be
used to validate predicted mutation phenotypes; this method is similar to the GFP reconstitution
assay discussed in Chapter 2 where a target intron is part of the construct.
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A last option that more closely resembles the configuration of photoreceptors in vivo is to
utilize retinal explants derived from donor tissue when a region of the retina is isolated and
maintained in cell culture media (Caffé, Visser, Jansen, & Sanyal, 1989). Retinal explants can be
cultured for several weeks and their survival has been improved by techniques including the
addition of physical tension to the tissue (Taylor, Moran, Arnér, Warrant, & Ghosh, 2013).
Techniques in explant maintenance are continuously being improved and experiments have been
conducted to validate transduction and transgene activity in human-derived explants (Orlans,
Edwards, De Silva, Patrício, & MacLaren, 2018). Despite these advances, the genetic background
of explant donors are inherently diverse so repeated experiments are subject to variability.
Acquisition of such human samples also imposes a limitation on the quantity of experiments that
can be performed during a study.
To develop a gene therapy strategy for Stargardt disease type 1, I hypothesized that a
maximum benefit pre-mRNA trans-splicing RNA editing strategy, previously modeled in CEP290,
would be applicable to edit transcripts of ABCA4. Due to the difficulties of modeling the gene, I also
hypothesized that manipulations to the promoter of ABCA4 could be performed which would allow
endogenous gene expression. This expression could then be targeted for proof-of-concept studies
of trans-splicing to the endogenous pre-mRNA.
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Results
Mutation diversity analysis of ABCA4
The first step when determining what gene therapy correction strategy can be used is to
determine what the significant mutation is, if any, and what strategy for correction can yield maximal
population benefit. However, there is no principally prevalent mutation in STGD1. There are several
databases of variants that include the Leiden Open Variation Database, curated by Frans Cremers,
and the Ensembl variation database, which references dbSNP and others. For visualization of
thousands of mutations, the VizGVar tool was developed which shows overlapping colored lines
for each type of mutation (Solano-Román, Alfaro-Arias, Cruz-Castillo, & Orozco-Solano, 2018).
Analysis of the ABCA4-201 transcript (ENST00000370225.3), hereafter referred to as ABCA4Full,
with VizGVar reveals a high density of missense mutations, synonymous mutations, and coding
sequence variations all of which are across the length of the coding sequence (Figure 3.2). While
the lack of a prevalent mutation will not help determine whether a 5’, 3’, or internal replacement
trans-splicing strategy should be utilized, it does suggest that there are a significant number of
mutations that can be corrected within the regions of coverage that can be obtained.

Figure 3.2 Annotated mutations in ABCA4Full. Data from the Ensembl mutation database for
the transcript ABCA4-201 was visualized with VizGVar.

ABCA4 is a good candidate for trans-splicing therapy.
The genetic landscape of ABCA4 is similar to the ubiquitously expressed CEP290, which
is associated with Leber Congenital Amaurosis (see Chapter 2). While CEP290 has 7,440 coding
nucleotides, ABCA4 has 6,822. CEP290 is comprised of 93,204 nucleotides across 54 exons while
ABCA4 is comprised of 128,313 nucleotides across 50 exons. We previously developed and
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validated a pre-mRNA trans-splicing molecule to edit the 5’ region of CEP290 and demonstrated
efficacy in a mouse mini-CEP290 model (Dooley et al., in submission and see Chapter 2). Because
of these similarities between the genetic landscapes, the same paradigm for maximum benefit
therapy design was predicted to work in ABCA4 (Figure 3.3).
A
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Coding DNA sequence length
(nucleotides)
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acids
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CEP290
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B

Figure 3.3 Comparison of ABCA4 and CEP290. (A) Features of the two genes and (B) primary
transcripts. Orange arrows in lower panels indicate an open reading frame.

The next step for designing a trans-

Exon Exon Size 5' PCDS 3'PCDS

splicing strategy for ABCA4 is to analyze
the coding sequence and determine the
maximum range that a pre-mRNA transsplicing

molecule

could

encode.

To

achieve this, I analyzed the principle
transcript, ABCA4Full, in a pre-mRNA transsplicing molecule (PTM) maximum benefit
table (Figure 3.4).
For a 5’ PTM, the partial coding

Intron Size Intron Name

17
18

66
90

2740
2830
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4569
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1,774

17-18
18-19
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20
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140
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3277
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20-21
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22
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4032
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22-23
23-24
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3700

2,692

24-25

25
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49

3900
3949

3615
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4,696

25-26
26-27

27
28
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4215
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3094

657
469

27-28
28-29

29
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4439

2969

796

29-30

30
31
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95

4626
4721

2870
2683

4,396
1,535

30-31
31-32

32

33

4754

2588

1,434

32-33

Figure 3.4 A trans-splicing maximum benefit table for
Homo sapiens ABCA4. Upward-facing arrow indicates
the range for a 5’ approach while downward-facing
arrow indicates the range for a 3’ approach. PCDS,
partial coding DNA sequence.

DNA sequence approaches the 3,500-nucleotide PCDS effective limit of recombinant adeno57

associated virus between the range of exons 21 and 24. Intron 21-22 is only 437 nucleotides in
length and would therefore be limited for the screening of binding domains since an ideal intron
size is comprised of 500 nucleotides or more. Therefore, I selected intron 22-23 as the target for
screening binding domains for pre-mRNA trans-splicing molecules which could edit the coding
sequence of ABCA4 up to and including c.3415 p.Ser1109. Additionally, based on the table, a 3’
PTM would likely target intron 26-27. The combination of these two PTMs would thus be able to
edit nearly 95% of annotated ABCA4 mutations.

Screening for ABCA4 5’ PTM binding domains in intron 22-23
After determining that ABCA4 intron 22-23 would offer the maximum 5’ benefit from premRNA trans-splicing, I used a green fluorescent protein reconstitution assay to identify effective
binding domains for a 5’ PTM (Koller et al., 2011). I designed a mini-gene comprised of ABCA4
exon 22, intron 22-23, and the 3’ coding sequence of GFP (Figure 3.5).

5’ GFP BD
Test PTM

CMV

5’ GFP

5’SS

Spacer

Binding Domain

polyA
GFP

3’GFP Mini-Gene
Target

Exon 22

3’GFP

polyA

Intron 22-23
3’ SS

Figure 3.5 Schematic of trans-splicing between a reporter and ABCA4 intron 22 target molecule.
Illustrations of a 5’ binding domain (BD) test pre-mRNA trans-splicing molecule (PTM) encoding the 5’
portion of green fluorescence protein (5’ GFP) and a mini-gene target encoding the 3’ portion of green
fluorescent protein (3’ GFP). Watson-Crick base pairing is indicated by vertical dashed lines. Transsplicing between the two pre-mRNAs results in reconstitution and expression of GFP.

Intron 22-23 lacks frequently cutting endonucleases that would generate fragments of the
desired 150-200 nucleotide size. Therefore, the binding domain library was generated by shortduration fragmentase digest of a PCR amplicon from intron 22-23 and cloned into a 5’ GFP reporter
vector. The reporter was transfected with the mini-gene target into HEK293T and evaluated by flow
cytometry after 48 hours. Binding domain clone 10 had the highest percentage of GFP positive
cells at 9.82%, followed by clone 2 at 5.19% (Figure 3.6). These numbers were approximately
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equal to the values seen in a similar screen for CEP290 (Dooley et al., in submission and see
Chapter 3).
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Figure 3.6 Flow cytometry of GFP
reconstitution assay for binding
domain screen in ABCA4 intron 22.
HEK293T were transfected with a 3’
mini-gene encoding ABCA4 exon 22,
intron 22, and the 3’ portion of the
coding DNA sequence of GFP. Cotransfection with a 5’ GFP binding
domain test pre-mRNA trans-splicing
molecule yielded GFP positive cells.
Quantification of positive cells as a
percent of total cells was performed by
flow cytometry.

Having identified a putative binding domain using the mini-gene system, the next challenge
was to evaluate the ability of this binding domain to edit endogenous ABCA4 pre-mRNA.

ABCA4Alt the unknown transcript
I first wanted to evaluate the expression of ABCA4 in the dedifferentiated state of iPSC

used cDNA from HEK293T cells. I evaluated ABCA4
expression using PCR with primers designed to amplify
a region between exons 45 and 48, which is predicted to
be a 324bp amplicon. While the lane for iPSC was
indeed negative, unexpectedly, the lane for HEK293T
was positive (Figure 3.7). Additionally, there were
several other minor higher mass bands present in the
retinal sample in addition to a bright band at the expected
size.
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Figure 3.7 PCR across ABCA4 exon
45 – 48 reveals expression in
HEK293T. cDNA was generated from
HEK293T cells, the retina of a human
donor, and induced pluripotent stem
cells derived from a healthy-vision
donor. Primers were designed in
ABCA4 exons 45 and 48 with a
predicted amplicon size of 324bp.

To determine the nature of ABCA4 expression in HEK293T, I evaluated public RNA-Seq
data sets for expression of this gene. Cell lines datasets of RNA-Seq detected some ABCA4
expression in several breast cancer lines. Tissue-based RNA-Seq using the Human Protein Atlas
dataset showed ABCA4 detection highest in epididymis at 9.9 transcripts per million and second
highest in kidney 6.2 at transcripts per million (Thul et al., 2017). Alignment of RNA sequencing
reads for three kidney samples to known ABCA4 transcripts showed an enrichment of reads at the
3’ end of the gene (Figure 3.8).

Figure 3.8 RNA-Seq alignments
to ABCA4 show unequal
expression across the gene in
three kidney samples. ABCA4 is
a minus strand encoded gene
and thus reads from right 5’ to
left 3’ in the upper diagram.
Average values across the
length of the reads for each
kidney sample are shown as
fragments per kilobase per
million (FPKM). Figure adapted
from ProteinAtlas.org.

Of the known alternatively spliced transcripts, only one is
ABCA4Alt

an alternative protein-coding transcript with a high level of
confidence of expression (ENST00000536513), and would
generate a predicted peptide of 1,065 amino acids. In silico
analysis of this open reading frame, hereafter ABCA4Alt, predicts
a peptide of 118.1 kDa with the first methionine corresponding to
Met1209 of ABCA4Full. This amino acid occurs just after the ATP-

2281

binding cassette motif of the first intracellular domain and prior to
the next transmembrane domain. Assuming similar folding to
ABCA4Full, this shorter

peptide will putatively retain an

extracellular loop and an intracellular region encoding an ATP-ase
active ATP-binding cassette (Figure 3.9).
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1209

Figure 3.9 Illustration of
ABCA4Alt predicted protein
folding across a phospholipid
bilayer.

I was unable to find any annotation of this transcript in the literature besides the RNA-Seq
databases. Interestingly, the murine homolog of the ABCA4 gene, Abca4, also has an alternative
transcript (ENSMUST00000141135.4) that would generate a predicted peptide of 1,102 amino
acids (122 kDa). No alternate transcripts have been detected in the current macaque genome
(MMul_8.01). Pairwise sequence alignment using the EMBOSS Needle algorithm of the human
and mouse ABCA4Alt predicted peptides shows 90.6% similarity (Goujon et al., 2010). Similarly, the
full-length peptides are 92.7% similar. The most significant region of difference between human
and mouse for either variant is the murine C-terminus, which has 38 additional amino acids before
the stop codon. These additional residues appear to result from an alternate terminal exon, as the
Homo sapiens terminal exon has only one amino acid followed by the stop codon. A C-terminus
VFVNFA motif, previously shown to be essential for localization to intracellular vesicles when
expressed in HEK293T, is also present in both the putative human and mouse variants (Zhong,
Molday, & Molday, 2009).
To determine possible splicing mechanisms for these transcripts, I evaluated the splice
sites identified by the RNA-Seq database. Based on alignment of the mRNA of ABCA4Alt to
ABCA4Full, the first nucleotide of ABCA4Alt is equivalent to exon 12 c.A1623. Oddly, ABCA4Alt does
not retain the entirety of exon 12 sequence and instead utilizes a putative splice site at c.G1629.
As reviewed elsewhere, there are two identified classes of introns with specific consensus splice
sites: U2-dependent also known as the major spliceosome and U12-dependent also known as
minor spliceosome (Turunen, Niemelä, Verma, & Frilander, 2013) (Figure 3.10).

Figure 3.10 Consensus alignments of ABCA4Alt splice sites. Upper, consensus motifs for U12 and U2 type
introns. Lower, Exons are numbered according to the splicing pattern of ABCA4Full. *Figure adapted from
Turunen et al., 2013.
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The c.G1629 locus in exon 12 is likely a weak U2-dependent 5’ splice site and cannot be
U12-dependent because the +5 position is not a “C”. According to the annotated sequence, this
transcript splices this site to a putative 3’ splice
site within exon 24 at c.G3561. This locus is likely

Analysis of all ABCA4Full splice junctions

a weak U12-dependent 3’ splice site and cannot
be U2-dependent because the -1 position is not
a “G”. The apparent incompatibility of these two
splice sites raises a concern about the validity of
the 5’ end of the reported transcript. The 3’ splice
site within exon 24 is particularly unique. I
performed a sequence logo analysis of all 5’ and

cccAC|GTGAAgtata

tctaagggtttctccaccAC|GTGtcc

Exon 12 internal 5’ss

Exon 24 internal 3’ss

Figure 3.11 Consensus alignments of all
ABCA4Full 5’ and 3’ splice sites. The height of a
letter indicates the fraction of that nucleotide at
the specific location across all samples analyzed.

3’ splice sites of ABCA4Full and found that no 3’
splice sites have a “C” nucleotide at the -1 location (Figure 3.11) (Crooks, Hon, Chandonia, &
Brenner, 2004; Schneider & Stephens, 1990).
After splicing into exon 24, ABCA4Alt then follows the same splicing pattern of ABCA4Full.
Lastly, the open reading frame of ABCA4Alt begins in exon 25 at c.A3625 p.Met1209 and reads
through to the normal termination codon. Therefore, 76bp within exon 12, the latter 47bp of exon
24, and the first 36bp of exon 25 constitute the 5’ un-translated region of this transcript.

ABCA4Full and ABCA4Alt expression in cell lines
I next expanded my analysis of ABCA4Alt expression to ask how ubiquitously it was
expressed in cell lines and if it could be translated. To validate that the protein extraction method
used was sufficient to identify ABCA4, I transfected HEK293T cells with a vector encoding
ABCA4Full. I first compared two lysis buffers and two polyacrylamide gel formulations to evaluate
the optimal conditions of isolation for endogenous ABCA4 from Y79 cells and utilized lysates from
the HEK293T transfected with ABCA4Full as a positive control. Regardless of conditions, exposure
still required up to 20 minutes for visualization. While a band was detected above 200 kDa on either
gel for HEK293T-ABCA4Full, a band of slightly higher mass was visible in Y79 extract isolated with
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radioimmunoprecipitation assay (RIPA) lysis buffer on a Bis-Tris 3-8% but not a Tris-Acetate 4-
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12% gel or on either gel for Triton-X100 lysis buffer (Figure 3.12).
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Figure 3.12 Western blot analysis
of ABCA4 with RIPA or Triton X100 extraction buffers. Lysates of
equal amounts of Y79 cells were
generated
with
either
radioimmunoprecipitation
assay
(RIPA) buffer or a Triton X-100
lysis buffer. Equal volumes of
lysate were size-separated in
either a Tris-Acetate 4-12% or BisTris 3-8% NuPage polyacrylamide
gel. Lysates from HEK293T cells
transfected
with a
plasmid
encoding ABCA4 and extracted
with RIPA were used as a positive
control
for
immunostaining.
Relative ABCA4 band density was
calculated
with
ImageJ,
standardized to α-Tubulin, and
normalized as indicated.

I next ran lysates from these HEK293T-ABCA4Full cells, the retinoblastoma cell lines WERI
and Y79, and the retinal pigment epithelial cell line ARPE19 on a western blot and probed with
higher concentrations of anti-ABCA4 antibodies. A bright band above 200 kDa was observed in
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Figure 3.13 Western blot analysis of ABCA4 in lysates from several cell lines. (A) Protein lysates from
cell lines were generated with radioimmunoprecipitation buffer and probed with anti-ABCA4 and anti-αTubulin antibodies. HEK293T cells were transfected with a plasmid encoding ABCA4Full as a positive
control (Lane 3). (B) Quantification of band density for both ABCA4Full at 260 kDa and the putative
ABCA4Alt at ~120 kdA was calculated with ImageJ, standardized to α-Tubulin, and normalized to 293T
ABCA4.
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(Figure 3.13, left). In Y79 and WERI, there were no significantly bright bands at the same mass,
though there were faint bands at higher and lower masses (Lanes 4, 5). No apparent band near
260 kDa was visible for ARPE19 (Lane 6). Interestingly, a band above 130 kDa by the PageRuler
Plus standard was present in lanes 1-4 but not lane 5. Densitometry analysis of this band,
standardized to the α-Tubulin loading control, showed higher levels of this band in HEK293T
transfected with ABCA4Full and that this level was equivalent to WERI cells (Figure 3.13, right).
Given the surprising appearance of this band in HEK293T cells transfected with ABCA4Full and the
mass difference between the bright upper band and the Y79 and WERI cells, I also performed
immunofluorescence to confirm published localization patterns (Figure 3.14) (Zhong et al., 2009).
DAPI

Merge

ABCA4Full

Untreated

ABCA4

Figure 3.14 Immunofluorescence of HEK293T transfected with ABCA4Full. HEK293T
cells were transfected with a plasmid encoding ABCA4 and processed after 48 hours
for immunofluorescence using anti-ABCA4 antibodies and counterstained with DAPI.

Finally, to specifically assess translation of the ABCA4Alt isoform, I generated a vector
encoding the predicted ABCA4Alt coding DNA sequence and transfected this into HEK293T.
Additionally, I designed short hairpin RNA to exons in ABCA4 with four conditions: (1) not predicted
to be part of ABCA4Alt (shEx10), (2) part of the ABCA4Alt mature mRNA (shEx12), (3) part of the
ABCA4Alt pre-mRNA (shEx15), or (4) a scrambled control (shCtrl). These shRNA were transfected
into Y79 cells and protein lysates were evaluated after 72 hours (Figure 3.15, left). Densitometry
analysis of the image showed the putative ABCA4Alt band at 120 kDa was 1.75 fold higher density
in 293T-ABCA4Alt when compared to 293T untreated (Lane 2 vs. 8) (Figure 3.15, right). There was
also an approximately 50% reduction of the 120 kDa band in Y79 treated with shEx12 or shEx15
64

but not shEx10 or shCtrl (Lanes 6 and 7 vs. lanes 5 and 6). Collectively, this data suggests that the
ABCA4Alt transcript is expressed in both 293T and Y79 cells and the 120 kDa band corresponds to
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the alternative transcript ENST00000536513.

Figure 3.15 Western blot analysis of ABCA4Alt in Y79 retinoblastoma cell line following shRNA
knockdown. (A) Western blot of cell lysates with treatments as indicated. Cells were transfected with
respective plasmids and lysates were harvested after 48 hours. (B) Densitometry quantification of the
band above 100 kDa. The image was quantified with ImageJ, values were standardized to α-Tubulin,
and normalized to untreated HEK293T.

Promoter activation of ABCA4
Successful evaluation of a trans-splicing strategy for targeting endogenous transcripts
requires the target to be present and expressed. While endogenous ABCA4 could be detected in
Y79, detection required a 20-minute exposure and it was not reliably reproducible. The alternately
spliced isoform could also be detected, but would likely not be a sufficient model for trans-splicing.
With induced pluripotent stem cell technology, we have the opportunity to generate cell lines that
harbor known pathological mutations if the gene is expressed. Recently, endonuclease-deficient
versions of the RNA-guided endonuclease Cas9 have been designed that retain the ability to target
specific loci without catalyzing a break in the DNA (Mali et al., 2013). Tethering three transactivation
domains to the C-terminus of Streptococcus pyogenes nuclease-null Cas9 (SP-dCas9-VPR) was
shown to stimulate gene expression at levels higher than the individual constituent transactivation
domains VP64, Rta, and p65 (Chavez et al., 2015).
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In collaboration with Devin McDougald and Laura Bryant, we designed guide RNAs to the
upstream region of ABCA4 (H. Liu et al., 2015). Devin also designed a guide-screening cell line by
transducing 84-31 cells with dCas9-VPR (84-31VPR) (Chirmule et al., 1999). Three putative guide
RNAs were transfected into this cell line and gene expression of ABCA4 was evaluated by RTqPCR after 48 hours using primers against the exon 8-9 junction. Guides are named based on their
location upstream of the transcription start site (TSS). Guide TSS-131 increased expression of
ABCA4 by over 300-fold and expression from guides TSS-58 and TSS-284 was increased 20 and
43 fold, respectively, when compared to non-transfected 84-31VPR (Figure 3.16).
A

B

ABCA4 Exon 8 – Exon 9 junction

84-31 CMV VPR
sgRNA ABCA4

A

g
s
sg sg5g13 131
58 8 1
a
an n
d ds
No Nosg2 g2
sg sg84 84
RN R
A N

ABCA4 Exon 8 – Exon 9 junction

s

84-31 CMV VPR
400sgRNA ABCA4
ABCA4Ex8-9
ABCA4 Ex8-9

300

300

200

200

100

100
0

0

U

Al

l
Al Sa
lS m
am pl e
pl s
es

GAPDH

Fold Change

GAPDH

400

Fold Change

N

C

TC

Untr
n
sg tereat
sgTS aetd
sg TSS0 ed
5
s TS S08
sggT S2 58
S
T 8
sg SSS24
TS 1384
S11
31

NT

Figure 3.16 RT-qPCR analysis
of ABCA4 expression in 8431VPR cells. Three putative
guide RNA for dCas9-VPR
were designed against the
ABCA4 promoter at locations 5’
to the transcription start site
(TSS). (A) Amplification curves
and threshold calculations of
RT-qPCR were performed with
primers across the ABCA4 exon
8 and 9 junction. GAPDH was
used as an endogenous control.
NTC, non-template control. (B)
Values were calculated by the
ΔΔCt method and normalized to
84-31VPR without a guide
transfection (Untreated).

Unfortunately, despite the increase in RNA expression, immunofluorescence imaging and
western blot analysis for ABCA4 did not show expression of protein in 84-31VPR_TSS-131 cells.
The Ct value, indicative of the abundance of DNA template, was 26 for TSS-131, while the
housekeeping gene GAPDH was 16. This difference of 10 Ct represents a 1000-fold difference
(2^ΔCt), though comparing values between primer sets is subject to variation. It is possible that the
level of induced ABCA4 expression may be below the amount necessary to generate protein that
can be detected by western blot.
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Macaque with retinal lesion and novel ABCA4 mutations
Large animal models of disease are often the gold standard for pre-investigational new
drug studies. To date, there has not been an identified large animal model of Stargardt disease
though advances in gene editing technologies will allow for the generation of models with specific
variant alleles. Determining if novel variants recapitulate disease in models will be of significant
interest. Recently, a 9 year old male macaque in an unassociated study was identified with bilateral
numerous macular spots (Figure 3.17) (Jean Bennett, personal communication).

Figure 3.17 Macular spots observed in a macaque. Right, 4x digital magnification of fovea.

We ran whole-exome sequencing on a sample from this animal to identify any putative
retinal degeneration associated genetic variants. In collaboration with Dr. Rando Allikmets, we
identified several mutations in ABCA4 when compared to the reference Macaca mulatta genome.
Importantly, two novel heterozygous ABCA4 variants were observed: c.2340 C>T p.(F780F) and
c.2460 G>C p.(Q820H). Neither variant had previously been observed in a database of 144
macaque genomes analyzed by Dr. Allikmets, which includes 27 samples with maculopathy. The
synonymous variant at c.2340 is predicted to enhance a strong cryptic 3’ splice site while the non-
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synonymous variant at c.2460 is predicted to be pathogenic. Dr. Allikmets suggested that these
two variants, if on separate alleles, could be highly pathogenic.
The two variants, which occur in exons 15 and 16, are 1,436 nucleotides apart and thus
can be amplified with one PCR product to facilitate allelic discrimination (Figure 3.18, top). To
further assess these variants, I generated primary dermal fibroblasts from a skin biopsy of both the
observed animal and a second animal with a healthy-appearing retina from another study. To
confirm heterozygosity at the loci, I then isolated genomic DNA and performed Sanger sequencing
of the PCR products. Mixed peaks were observed at the expected loci for both c.2340 and c.2460
in the lesion-harboring animal sample, but, unexpectedly, a similar mixed peak was observed in
the healthy-retina sample at c.2460 (Figure 3.18, bottom left). For allelic discrimination, I performed
topoisomerase-based cloning techniques on the PCR product amplified from the sample of the
animal with spots to isolate the two alleles (Shuman, 1991, 1994). Sanger sequencing of 10 clones
revealed two distinct populations correlating to two alleles: (1) 5 samples with c.2340C and c.2460
G>C and (2) 5 samples with c.2340 C>T and c.2460G (Figure 3.18, bottom right).
Alignment between macaque and human ABCA4 coding sequences shows substantial
similarity in both coding exons as well as non-coding introns. The peptide sequence is 98.11%
similar while the coding DNA sequence is 97.41% similar, and both comprise 2,273 amino acids.
Direct comparisons of the entire intron 22-23 sequence shows only 90% similarity, and specifically
for the 223bp range of binding domain 10, there are 16 single nucleotide polymorphisms and 1
deletion of four nucleotides in the macaque homologous range. While ABCA4Full is not expressed
in fibroblasts, the identification of this animal with a phenotype and novel variants opens exciting
possibilities for a new model that can be used to study trans-splicing of ABCA4.
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Figure 3.18 Sanger sequencing of macaque gDNA samples shows novel mutations in ABCA4. Primary
dermal fibroblasts were cultivated from a macaque with numerous bilateral macular spots resembling a
Stargardt disease phenotype and from a macaque with a healthy retina. Sanger sequencing was
performed on genomic DNA. (A) Illustration of the Macaca mulatta ABCA4 exon 15 and 16 locus where
novel variants were detected by whole exome sequencing. FWD, forward primer. REV, reverse primer.
(B) Sanger sequencing of whole PCR products from either the healthy or lesion sample. Yellow box
highlights IUPAC ambiguity codes: Y = “C” or “T”, S = “G” or “C”. (C) Sanger sequencing of cloned PCR
products from the Stargardt-like sample. 5 reads were identified per allele with single nucleotide
polymorphisms as indicated.
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Discussion
Therapies for ABCA4-mediated diseases including Stargardt, cone-rod dystrophy, retinitis
pigmentosa, Leber Congenital Amaurosis, and age-related macular degeneration are significantly
lacking and there is a substantial unmet need in the vision community. As the most prevalent form
of juvenile macular degeneration, STGD1 is an attractive candidate for gene therapy because of
the large patient populations that could benefit from a possible rescue. However, developing such
a therapy is hampered by the many challenges explored here. Tissue-specific expression of ABCA4
limits the simplicity of study when compared to a ubiquitous gene such as CEP290. Though there
have been a handful of reports on ABCA4 expression in tissues other than photoreceptors, there
have been no follow-up studies on these reports. Some variants of ABCA4 do appear to be
expressed in various locations, and here I identified a variant that encompasses the 3’ half of the
gene. However, this is still not an ideal model of expression.
The diverse range of mutations within ABCA4 suggests that survival of an organism
tolerates mutations fairly well, but this also means that a corrective therapy must have broad
application. Complete gene augmentation would be ideal as STGD1 and other ABCA4-mediated
diseases present as autosomal recessive; however, the coding DNA sequence is too large for AAV
delivery. Alternative delivery through the equine infectious anemia virus based SAR422459,
previously known as StarGen, is the most promising agent so far and is currently in a phase I/II
clinical trials (NCT01367444 and NCT01736592) (Binley et al., 2013; Kong et al., 2008). However,
to date, there has not been a data release from this trial so it remains yet to be seen if this approach
will confer therapeutic efficacy.
As an alternative therapeutic approach that utilizes recombinant adeno-associated virus, I
evaluated ABCA4 as a candidate for pre-mRNA trans-splicing. As with CEP290, the maximum
benefit table showed that ABCA4 is an ideal candidate for this potentially broad editing strategy.
By replacing the entirety of the first 3,415 nucleotides, a single molecule would be eligible for the
correction of close to 50% of annotated mutations in ABCA4. Additionally, a 3’ pre-mRNA transsplicing molecule would be able to correct nearly the entire 3’ region. These two approaches
combined could correct the bulk of known ABCA4 mutations. One important consideration though
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is the heterogeneous nature of patient mutations. Two of the samples that were derived into
induced pluripotent stem cells in the Bennett lab are compound heterozygous, and both mutations
in either patient are within the range of correction for the 5’ approach. However, there are additional
patient samples that do not fall into this category. Indeed, several are a mixture of what are
considered 5’ and 3’ mutations in this study. If a trans-splicing approach was capable of correcting
100% of transcripts, this would mean an approximately 50% correction maximum for heterozygous
patients with mixed 5’ and 3’ mutations.
This may still be sufficient, since the effective level of correction remains to be determined
for STGD1. Parents of Stargardt patients often have healthy vision for most of their lives despite
having at least one mutation that can lead to pathogenicity. The highly dysmorphic nature of ABCA4
suggests that mutations are well tolerated for survival. Correction of some minimum portion of
transcripts may be able to at least slow the degeneration. Several studies have suggested that
“mild” ABCA4 mutations are also associated with age-related macular degeneration (AMD). This
may be the result of reduced efficiency of all-trans-retinal membrane transit. In contrast, “severe”
ABCA4 mutations result in rapid onset of juvenile macular degeneration that is characteristic of
Stargardt disease and cone-rod dystrophy. In the most ideal sense, gene therapy for STGD1 could
also have a benefit for AMD.

Splice variants of ABCA4
A significant consideration for gene therapy is to ensure that you deliver the correct version
of a gene. Typically, referencing the annotated human genome and picking the corresponding
transcript achieves this. However, some genes have several annotated isoforms. Tissue-specific
splicing patterns can add a layer of complexity to this selection. Retinal genes pose an additional
challenge when considering these possible alternative transcripts. In the large human genome and
transcriptome databases, retinal tissue is often not presented as a separate category. Yet it is
known that photoreceptors have increased levels of splicing factors and there are more alternative
transcripts in the retina than in other tissue. It is not entirely surprising then that analysis of retinal
cDNA with the exon 45-48 primer pair showed extra bands in cDNA from retina that were not
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present in HEK293T. These additional bands may be other minor alternative splice products
resulting from enriched splice variation. The sensitive nature of PCR also makes for the possibility
that the observed bands are simply artifacts or one-off mis-spliced transcripts. While this may be
possible for the retinal samples, the band of expected size observed in the samples from HEK293T
was far more interesting.
The possibility that ABCA4Alt is a transcript with a cellular function is quite intriguing. This
alternative transcript encodes essentially the 3’ half of the gene including the ATP-ase active
nucleotide-binding domain in the intracellular C-terminus. The precise nature of this putative
peptide and possible functions are yet to be elucidated. By expressing the predicted open reading
frame, I was able to detect a band of the expected size in HEK293T. This band matched a band
visible in previous blots with ABCA4, suggesting that ABCA4Alt is expressed in HEK293T, Y79, and
WERI but not ARPE19. Using short hairpin RNA to knockdown this transcript also indicates that
the pre-mRNA arises from a separate transcriptional event than ABCA4Full. Further profiling of this
variant and its function will be necessary to understand any possible functions. With an ATP-ase
domain, the peptide is likely biologically active. Reconstitution of ABCA4Alt will be necessary to
confirm the turnover of ATP to ADP + Pi. Additionally, the peptide may form complexes with other
proteins

that

can benefit from

a conformational change,

and techniques

such as

immunoprecipitation followed by mass spectrometry may be able to elucidate such binding
partners.
Oddly, overexpressing ABCA4Full in HEK293T also increased the level of ABCA4Alt. The
coding sequence used in this study was codon-optimized. The algorithm used for optimization is
designed to also remove cryptic splice sites. The observed increase of the 120 kDa band, therefore,
was unexpected when transfecting the full 290 kDa coding sequence. Further experiments will be
required to identify if the ABCA4 peptide is capable of being cleaved to generate a half-size peptide,
or if expression of ABCA4Full stabilizes ABCA4Alt. While ABCA4Alt appears to be predicted as a
splicing variant by RNA-seq, the lack of a splice site in the codon-optimized sequence and the
apparent mismatch of U2- and U12-type introns suggests that another mechanism may be
generating the 118.1 kDa variant observed in HEK293T, WERI, and Y79 cells. Additional studies
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of ABCA4Alt will help resolve the properties and potential functions of this ATP-ase containing
peptide.
With ABCA4Full, the second extracellular domain has been shown to tightly bind all-transretinal (Biswas-Fiss, Kurpad, Joshi, & Biswas, 2010). Contrasted with the earlier findings that NRPE is also bound to the second extracellular domain, this finding poses questions about exactly
which form of all-trans-retinal is bound to ABCA4 and what is the actual biological role of the protein
(Pollock & Callaghan, 2011). If indeed the 3’ half of ABCA4 is expressed in other tissues including
kidney, then it is possible that ABCA4 serves minor biological functions associated with retinoid
molecules in tissue besides the eye or may have activity with non-retinoid molecules. In opposition
to this is that ABAC4 has not been implicated in any pathology other than ocular disease. The
nature of ABCA4Alt may therefore be of interest for studies of the gene but not necessarily for the
treatment of human disease.
While not perfect since it would not have the ability to model patient mutations, the
alternative transcript may serve a potential use for modeling the trans-splicing approach if other
models are unable to be generated. Since the ABCA4 5’ PTM targets intron 22 while 3’ PTM targets
intron 25, both are predicted to be encoded on the pre-mRNA of ABCA4Alt. If trans-splicing were
entirely successful, then a novel full length ABCA4 product should be generated in HEK293T cells.
This would provide a simplified readout of expression with confidence that ABCA4 can fold in these
cells

since

overexpression

in

HEK293T

can

be

detected

in

the

cytoplasm

with

immunofluorescence.

Induction of ABCA4 Expression
While ABCA4Alt provides a glimmer of possibility for modeling RNA editing strategies in
cultured cells, Y79 cells or WERI cells are better models because they express the full length of
the pre-mRNA. The impact of upstream sequence has not been resolved with regards to RNA
editing, so preliminary studies should ideally be performed using a target molecule that is as similar
to the final target, ABCA4Full, as possible. However, the level of ABCA4 in these cells is extremely
low. Despite several variations of extraction methods and polyacrylamide gel conditions, detection
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of endogenous protein requires a high concentration of antibody and long exposures with
chemiluminescent assays. As evidenced by the CEP290 5’ PTM studies, trans-splicing with the
current PTM genome occurs at a low rate. Transfection of PTM genomes in cultured cells resulted
in far higher rates of trans-splicing than transduction of PTM genomes with recombinant adenoassociated virus (rAAV). Contrarily, the detection of trans-splicing was significantly higher in a
mouse model following sub-retinal injection of rAAV-PTMs. This model has more copies of the
target gene than an endogenous gene and therefore more pre-mRNA availability. In the case of
Y79 and WERI, the pre-mRNA levels are likely quite low. This would be a significantly limiting factor
for the study of ABCA4 PTMs.
The advent of CRISPR/Cas9 technologies has started a major revolution in the field of
gene editing for both research and therapeutic use. As RNA-guided nucleotide binding proteins,
the Cas family brings multiple opportunities for scientific engineering. In addition to the capacity for
direct gene editing, the nuclease-deficient version tethered to transactivation domains has resulted
in programmable transcription factors. Here, we showed proof-of-concept that this system can be
utilized to enable expression of ABCA4 in HEK293T. Initially, we were concerned that ABCA4 may
exist in a tightly controlled heterochromatic state, but one of our guide RNA stimulated expression
from minimally detectable to several hundred-fold higher. Relatively, this level is still a thousandfold lower than a housekeeping gene and we were unable to detect protein with either western blot
or immunofluorescence. The candidate guides used in this pilot study were chosen from the top
predictions of one guide selection tool. When analyzing the ABCA4 promoter in other guide
selection software, the predicted guides do not match the ones used in this study. Therefore, it is
likely that improved guide RNA can be identified to drive further expression of ABCA4, potentially
to levels that would allow for detection of ABCA4 protein. Also, other studies have shown that
adding more than one guide can further stimulate expression. There are thus many opportunities
to improve the stimulation of ABCA4 expression in otherwise non-expressing cell lines.
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Patient-derived promoter-activated cell lines
Evaluating patient mutations in patient-derived tissues is rapidly becoming a standard
practice. For tissue-specific genes such as ABCA4, this type of modeling is inherently more difficult
as the cell of interest is not easy to maintain ex vivo. Stem cell technologies have made great
advances and the possibility of utilizing photoreceptor precursor cells now means that ABCA4 can
be modeled in vitro. Another student in the Bennett Lab is studying the generation of organoids as
a model for another disease, and efforts within our lab are ongoing to generate a reliable and
efficient protocol for photoreceptor precursor cells. The Center for Advanced Retinal and Ocular
Therapeutics (CAROT) iPSC Core, which manages patient-derived samples from the Bennett Lab,
has generated cell lines from two patients with Stargardt disease:
•

JB363 Ex6 c.655A>T p.(Arg219Stop) het; Ex6 c.664delG p.(Ala222fs) het

•

JB437 Ex12 c.1622T>c p.(Leu541Pro) het; Ex 21 c.3113C>T p.(Ala1038Val) het

The complex allele L541P A1038V is common amongst those of German decent and represents
one of the more predominant mutations in ABCA4 (Rivera et al., 2000; N. Zhang et al., 2014).
These cell lines were validated for genotype and iPSC markers, but no studies have been
performed with them to assess expression patterns of ABCA4.
These cells may prove valuable in future studies that utilize promoter activation or
photoreceptor precursor derivation. As one genotype encodes a pair of missense mutations while
the other encodes a nonsense mutation and a frameshift mutation leading to an early truncation, I
can make some predictions about the residual function of ABCA4: (1) wild-type cell lines would be
positive for RNA, protein, and ABCA4 functions, (2) JB437, harboring two missense mutations,
would be positive for RNA and protein but have lower rates of function, and (3) JB363, harboring
two truncating mutations, would likely have nonsense-mediated decay of RNA, a total lack of
ABCA4 protein, and a resulting total absence of function.
Beyond the interests of gene activity analysis, since all patient mutations occur prior to
intron 22-23, both patients are predicted to have a bi-allelic benefit from 5’ pre-mRNA trans-splicing
targeting intron 22-23. This means both samples are ideal candidates for modeling this gene editing
approach. Success with promoter activation would enable proof-of-concept studies for validating
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the 5’ PTMs designed in this current study. The next step would then be an in vivo study. Contrary
to our CEP290 study, which utilized a mouse harboring a humanized mini-gene, there is not a
humanized mouse model for ABCA4. Also, introns are not well conserved between human and
mouse, so the complementarity of binding domains is likely not well preserved.

Large animal studies
Primates are the closest in genetics to humans, but some of the same concerns for
sequence conservation apply. Despite high conservation of the coding DNA sequence, introns are
less well conserved. There has not been an extensive study performed on binding domains to
determine the effect of mismatches on the efficacy of binding. A future trans-splicing study of a
human designed PTM delivered to macaque cells could provide a foundation for potential efficacy
in the large animal model. Also, identification of a macaque with novel ABCA4 mutations presents
an exciting opportunity to generate a colony with a maculopathy phenotype. Unfortunately, the
study protocol under which the animal was treated required euthanasia before we could procure
samples necessary for breeding. However, the fibroblast cell line remains a potentially useful
resource for studying ABCA4 expression. Promoter activation may be used to stimulate expression
and see if predicted genotype-phenotype correlations can be validated in fibroblasts. The cells
could also be dedifferentiated into iPSC and utilized in myriad ways for further analysis. Also, the
first cloned macaques were recently reported (Z. Liu et al., 2018). Such technology could be utilized
to recreate the animal from which the fibroblasts were sourced. Perhaps more easy, though, would
be to identify relatives of the animal and establish a new breeding colony.
Unexpectedly, analysis of genomic DNA from a macaque with a healthy-retina, used in an
unassociated study, also revealed the presence of heterozygosity at the ABCA4 c.2460 locus. This
mutation was not seen in any of Dr. Allikmets previous samples and indicates that the animal was
sourced from a colony related to the lesion-afflicted animal. This possibility gives hope that we
could identify both alleles within the population and then attempt to breed an animal that would
harbor a similar genotype and phenotype as the observed animal. It is also consistent with the
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human hereditary pattern where parents can be silent carriers of a deleterious heterozygous
mutation.
Collectively, my work on ABCA4 has highlighted the challenges of designing a gene
therapy strategy for STGD1 and other forms of retinal degenerative disease. In this study, I aimed
to apply the trans-splicing paradigm previously designed for CEP290 to identify a 5’ pre-mRNA
trans-splicing molecule to edit and correct transcripts of ABCA4. Identifying a binding domain with
a screen yielded trans-splicing at similar levels to previous studies. The next step of converting that
binding domain to yield corrected ABCA4 was hindered due to a lack of ABCA4 expression in
cultured cells. For two lines that are commonly said to express the protein, the levels are too low
for trans-splicing detection. To overcome this hurdle, I explored the use of RNA guided nucleases
to bring transcription factors to the promoter of ABCA4 and increase gene expression. This pilot
study was successful at increasing the abundance of ABCA4 transcript but was not able to produce
visible protein. In a future study, these new technologies can be used to explore ABCA4 expression
in patient cell lines and macaque lines to demonstrate proof-of-concept editing prior to in vivo
administrations of pre-mRNA trans-splicing molecules.
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Materials and Methods
Mutation analysis
Mutations of the ABCA4-201 transcript present in the Ensembl dataset were visualized with
the Visualization Portal for Genetic Variations (VizGVar, http://vizport.io/vizgvar/) (Solano-Román
et al., 2018).

Sequence alignments
Sequence alignments and similarity comparisons for nucleic acids and amino acids were
performed with Pairwise Sequence Alignment Needle (EMBOSS) tool available at the European
Bioinformatics Institute (https://www.ebi.ac.uk/) (Needleman & Wunsch, 1970). Reference genome
versions include: Mus musculus GRCm38.p5, Macaca mulatta MMul_8.0.1, and Homo sapiens
GRCh38.10. Coding DNA sequences for primary ABCA4 transcripts were identified via the
Ensembl database (http://useast.ensembl.org/) with the reference sequences of Macaca mulatta
ENSMMUT00000019452.3 and Homo sapiens ENST00000370225.3. Tissue and cell based gene
expression from RNA-Seq databases were visualized with version 15 of the Human Protein Atlas
(https://v15.proteinatlas.org).

3’ GFP mini-gene target generation
The 3’ GFP target mini-gene was generated by infusion cloning to replace the CEP290
exon 26 intron 26 region of pLX302 CEP290 I26 3’ GFP (see Chapter 3) with the ABCA4 exon 22
intron 22 region. PCR was used to amplify the backbone of pLX302 3’ GFP with primers pLX
vectorFOR 3pGFP 5’ - GTG AAG TTC GAG GGC GA - 3’ and pLX vectorREV Myc 5’ - TTC AGA
TCC TCT TCT GAG ATG AGT - 3’. PCR was also used to amplify ABCA4 Exon 22 and Intron 22
from a healthy-donor genomic DNA with primers hABCA4 fragFOR E22 5’ - AGA AGA GGA TCT
GAA GTG GCA TGC AGA GAA AGC and hABCA4 fragREV I22 5’ - GCC CTC GAA CTT CAC
CTG CAA GGT AGG GGC C – 3’. PCR products were visualized by agarose gel electrophoresis
and extracted with Nucleospin PCR and Gel Cleanup Kit (Machery-Nagel 740609.5). In-fusion
master mix (Clontech 638909) was used to ligate the two PCR products. The ligated reaction was
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transformed to STBL2 cells (Invitrogen 10268019) on 100 µg/mL ampicillin LD-Agar plates and
incubated overnight at 30C. Bacterial cultures were grown in LB with 100 µg/mL ampicillin and
plasmid was purified with a Qiaprep Spin Miniprep kit (Qiagen 27106). Final mini-gene plasmids
were validated by Sanger sequencing with CMV FW 5’ - CGC AAA TGG GCG GTA GGC GTG –
3’ and GFP RV 5’ - GCC ATC CTC CTT GAA ATC GG – 3’.

Binding domain library generation
ABCA4 intron 22 was amplified from healthy-donor genomic DNA with primers hABCA4
I22 frag FW 5’ - AGC TGC TGC TCA GTC TCC TGG – 3’ and hABCA4 I22 frag RV 5’ - AGG GGC
CAG GGC AAT CAC – 3’. The band was visualized by agarose gel electrophoresis and column
purified with Nucleospin PCR and Gel Cleanup Kit (Machery-Nagel 740609.5). Purified PCR
product was digested with NEBNext dsDNA Fragmentase (NEB M0348) for 30 minutes followed
by column purification. The 5’ PTM no binding domain plasmid (gift from Lloyd Mitchel,
RetroTherapy, LLC, Bethesda, Maryland) was digested with EcoRV-HF (NEB R1395),
dephosphorylated with rSAP (NEB M0371), and column purified. The ABCA4 intron 22 pool of
fragments was ligated to 5’ PTM NBD with T4 DNA Ligase (NEB M0202). Ligated samples were
transformed to OneShot Top10 competent E. coli per manufacturer’s instructions (Invitrogen
C404003). 24 colonies were cultured and Sanger sequenced via V5 tag RVseq 5’ GGA GAG GGT
TAG GGA TAG GC – 3’ and unique clones were selected for transfection.

Library screening in HEK293T
10,000 HEK293T cells per well were plated in each well of a 24-well cluster dish. The next
day, cells were transfected with Lipofectamine LTX (Invitrogen 15338100) with Lipofectamine alone
or 1 µg of ABCA4 intron 22 target 3’ GFP mini-gene alone, 5’ PTM 5’ GFP clones alone, or 1 µg
each of 5’ PTM 5’GFP clones and ABCA4 intron 22 target 3’ GFP mini-gene. At 72 hours post
transfection cells were washed with PBS, dissociated with Trypsin-EDTA 0.05% (Invitrogen
25300054), re-suspended in PBS, and evaluated with a BD AccuriC6 Flow Cytometer. Samples
were gated for GFP positivity by the fluorescence intensity of untreated cells.
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Expression detection of ABCA4
RNA was isolated from HEK293T or induced pluripotent stem cell pellets with RNEasy Mini
Kit (Qiagen 74134). RNA from the retina of a human eye was a gift from Aaron Black, Bennett Lab.
1 µg of RNA was used for cDNA generation with Superscript II 1st Strand Synthesis Kit (Invitrogen
11904018) with Oligo(dt) primers per manufacturer’s instructions. ABCA4 expression was detected
in cDNA using Q5 2x Master Mix (NEB M0492) polymerase and primers ABCA4 Ex45FW 5’ GAA
ACT CTC CAC AGC CAT CG – 3’ and ABCA4 Ex48RV 5’ - ACA GGG TTC AGG TCA GGA AG –
3’.

Western blot analysis of ABCA4
Protein lysates were generated with radioimmunopreciptation (RIPA) buffer (Cell Signaling
Technologies 9806) or Triton-X100 Buffer consisting of 150 mM sodium chloride, 1.0% v/v Triton
X-100 (Roche 10789704001), and 50 mM Tris pH 8.0. Cell pellets were re-suspended in 1:1 volume
lysis buffer, vortexed for 30 seconds, rotated end over end for 1 hour, vortexed for 30 seconds,
centrifuged 17,900 x g for 20 minutes, and supernatant was transferred to chilled microcentrifuge
tubes. Protein concentrations were determined with MicroBCA Assay (Pierce 23235) per
manufacturer’s instructions. 40 µg of protein was mixed with LDS (Invitrogen NP0007) and 1M
dithiothreitol (Sigma D9163) and incubated 37°C 30 minutes. Denatured protein samples were
loaded to NuPage gels as indicated and electrophoresis was run at 50V for 15 minutes followed by
150V for 60 minutes until the dye front reached the foot of the gel. Samples were transferred to
methanol-activated polyvinylidene difluoride membranes with the XCell II system (Invitrogen) per
manufacturer’s instructions at 30V for 1 hour in 5% methanol NuPage transfer buffer (Invitrogen
NP0006).
Membranes were incubated in blocking buffer comprised of 5% w/v non-fat dry milk
(LabScientific Inc M-0841) in Tris-buffered Saline with 1% Tween-20 (TBST) (Cell Signaling
Technology 9997S). Membranes were incubated overnight at 4°C with primary antibodies diluted
in blocking buffer. Antibodies include: ABCA4 3F4 (Abcam 77285) 1:500 and α-Tubulin DM1A (CST
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3873) 1:2000. Membranes were then washed three times for 15 minutes TBST. Membranes were
incubated for 1 hour at room temperature with secondary antibodies diluted in blocking buffer.
Secondary antibodies include: Amersham ECL Mouse IgG HRP-linked (GEHealthcare NA9310).
Membranes were then washed three times for 15 minutes TBST. A chemiluminesence reaction
was performed with ECL 2 Substrate (Pierce 80196) according to manufacturer’s instructions.
Detection of the reaction was performed with AI600 Chemiluminescent Imager (GEHealthcare)
using chemiluminsesence settings for 20 minutes exposure. Intensity of reactions indicating protein
concentration were calculated with ImageJ and standardized to α-Tubulin.

shRNA Screen
Knockdown of ABCA4 was achieved with RNAi Consortium shRNA Library(Moffat et al.,
2006) sequences against ABCA4: TRCN0000059375, TRCN0000059373, and TRCN0000423663.
The shCtrl plasmid was generated with:
pLKO CTRL TOP 5’ – CCGGTCCGCAGGTATGCACGCGTG – 3’ and pLKO CTRL BOT 5’ –
AATTCACGCGTGCATACCTGCGGA – 3’. The sequences were cloned into the EcoRI and AgeI
site of the pLKO.1 vector per suggested protocols (AddGene, 2006). The pLKO.1 - TRC cloning
vector was a gift from David Root (Addgene plasmid # 10878).
Final plasmids were sequence verified by Sanger sequencing with a U6 Forward primer 5’
– CAAGGCTGTTAGAGAGATAATTGGA - 3’. 2.5 µg of each plasmid was transfected to 1 x 106
Y79 cells. Protein lysates were obtained after 72 hours (see Western blot analysis section).

Promoter Activation
SP-dCas9-VPR was a gift from George Church (Addgene plasmid # 63798) (Chavez et al.,
2015). 84-31 cells (Chirmule et al., 1999) expressing dCas9-VPR were developed by Devin
McDougald. sgRNA were selected with CRISPR-ERA tool (http://crispr-era.stanford.edu/) using the
upstream 1,000 nucleotides of ABCA4 gene as a template and settings Gene Activation, hg19,
ABCA4 NM_000350.
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I selected the top two guides using CRISPR-ERA “Default” parameter and the top guide
using “U6 Promoter” parameter. The top hits are named relative to the nucleotide closest to the
transcriptional start site (TSS). These were 131, 58, and 284. TSS-131 was the top result for “U6
Promoter” parameter while 58 and 284 were the top result for the “Default” parameter.
•
•
•
•
•
•

ABCA4 TSS131 TOP 5’ accGACACAAGTGGCTGGGCACC 3’
ABCA4 TSS131 BOT 5’ aacGGTGCCCAGCCACTTGTGTC 3’
ABCA4 TSS284 TOP 5’ accATAGGCTGGGCATTTGTCCT 3’
ABCA4 TSS284 BOT 5’ aacAGGACAAATGCCCAGCCTAT 3’
ABCA4 TSS58 TOP 5’ accATAAGCCCTTAGTTGGGGAG 3’
ABCA4 TSS58 BOT 5’ aacCTCCCCAACTAAGGGCTTAT 3’
Guide RNA oligos were ordered from IDT and cloned into a U6 guide expression plasmid

PX552. PX552 was a gift from Feng Zheng (Addgene plasmid # 60958) (Swiech et al., 2015).
Cloning was performed via AddGene protocol 60958 PX552 (Zhang Lab). PX552 was digested
with SapI (NEB R0569) and dephosphorylated with rSAP (NEB M0371). The backbone was
isolated by agarose gel electrophoresis and column purified. Oligos for guide RNA were
phosphorylated with T4 PNK (NEB M0201) and anneal using 1 µL of 100 µM each in PNK Buffer
with thermocycling conditions 37°C 30m, 95°C 5m, ramp to 4°C 0.1°C/s. Annealed and
phosphorylated oligos were ligated to PX552 with T4 Ligase (NEB M0202) per manufacturer’s
instructions. All plasmids were validated by Sanger sequencing.
One day before transfections, 10,000 84-31VPR cells were plated per well of a 24-well
cluster plate and incubated overnight at 37°C 5% CO2. On the day of transfection, 1 µg of sgRNA
plasmids were transfected in duplicate wells with Lipofectamine LTX (Invitrogen 15338100) per
manufacturer’s protocol. GFP expression was visualized by fluorescence microscopy in all
transfected samples. After 72 hours, cells were washed with PBS, dissociated with 0.05% TrypsinEDTA, and washed with PBS. RNA was extracted with RNEasy Plus Mini kit (Qiagen 74134) and
cDNA was generated from 1 µg of RNA using 1st Strand Synthesis system (Invitrogen 11904018).
20 ng of cDNA per reaction were prepared with Power Sybr master mix (Applied Biosystems
4367659) per manufacturer’s instructions with primers: ABCA4 Ex8A FW 5’ - CTT TCT GGG GAT
TGA CTC CA – 3’ and ABCA4 Ex9A RV 5’ - CCT CCA AGC GAT TTT GGT TA – 3’, and the
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endogenous control GAPDH-FWq 5’ - CCA CTC CTC CAC CTT TGA C – 3’ and GAPDH-RVq 5’ ACC CTG TTG CTG TAG CCA – 3’.
Thermocycling was performed with a 7500 FAST apparatus (Applied Biosystems) using
standard cycling for ΔΔCt with melting curve steps added. Fold changes and confidence intervals
were calculated with ExpressionSuite Software v1.1 (Applied Biosystems).

Generation of primary dermal fibroblasts
Primary dermal fibroblasts were generated as previously described (Vangipuram, Ting,
Kim, Diaz, & Schüle, 2013). A dermal skin biopsy was obtained and stored in phosphate buffered
saline (PBS) (Mediatech MT21030). 0.1% gelatin (Sigma G1393) was added to each well of a 6well cluster plate and incubated for 30 minutes at room temperature. The biopsy was transferred
to an inverted 10 cm tissue culture dish lid with 1 mL of complete media consisting of Dulbecco’s
Modified Eagle’s Medium (Invitrogen 10569010) supplemented with Penicillin-Streptomycin
(Invitrogen 15140122) and 20% fetal bovine serum (HyClone SH30910.03). The sample was
dissected with two ethanol-sterilized razor blades into one-millimeter fragments. Gelatin was
aspirated from cluster plates and 800 µL of complete media was added. 4-6 fragments were
transferred to each well and plates were incubated at 37°C 5% CO2 for 48 hours. 200 µL of
complete media was added as necessary to maintain a film of media over the biopsy fragments
through one week. Media was aspirated and fresh media added every 2-3 days until fibroblast
colonies were dense and had reached the walls of the chamber. Cells were then washed with PBS
and dissociated with 0.25% Trypsin-EDTA (Invitrogen 25200056). Dissociated cells were then
neutralized with complete media, pooled, and passaged to 2 x 10 cm tissue culture dishes. When
confluent again, cells were passaged to 3 x 15 cm tissue culture dishes for passage 2. Confluent
passage 2 fibroblasts were then passaged for experiments or cryogenically preserved in complete
media supplemented with 10% dimethyl sulfoxide (Sigma D2650).
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CHAPTER 4 Methodical library design for binding domain synthesis

Introduction
The generation of binding domain libraries has taken several approaches. I modeled my
binding domain screens for CEP290 and ABCA4 after a low-throughput method used to
approximate efficacious binding domains. In a trans-splicing study of KRT14, sonication was
utilized to generate a library of over 10,000 candidate binding domains (Wally et al., 2010). Despite
the vast size, the best identified binding domain yielded only 15% GFP positive cells using a GFP
reconstitution assay (Uchida et al., 2017; Wally et al., 2010). This data matched the output
observed in my low-throughput screens (see Chapters 2 and 3). A more methodical analysis of
target regions could potentially yield better hits and help determine whether or not there are specific
loci at which a binding domain is rendered efficacious or unable to bind to a target. Such loci may
be missed using sonication or other randomized screening methods. Refinement to the core size
of a binding domain and identification of active versus inactive nucleotides within the domain may
help facilitate an understanding of the biology of trans-splicing activity and the specificity conferred
by binding domains. The generation of libraries has thus mostly been based on randomization or
the presence of particular restriction endonuclease sites.
Improved synthesis of oligonucleotides has reduced the price of synthesizing
oligonucleotides (oligos). Commercially available resources allow mass production of oligos for
screens used in knockdowns and other techniques. Gene blocks are now a go-to method for
designing plasmids and are often cheaper and faster than several rounds of cloning. For highthroughput screens, designing the oligo pools to be ordered often is a time consuming process. To
define a methodical approach to binding domain library creation, I hypothesized that an iterative
algorithm could be designed and applied to any input sequence and automatically output a diverse
binding domain screen.
Microsoft Excel has both standard spreadsheet features and a Developer add-in that
includes the scripting language Visual Basic for Applications (Microsoft, n.d.). By being able to write
custom scripts, this combination allows for spreadsheets that can perform more complex functions
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including functions similar to those in programming suites such as R Studio, which are more
specifically designed for biological analysis. Here, I demonstrate an algorithm to generate complex
libraries of oligonucleotides that could be synthesized and cloned to perform high-throughput
methodical analysis of binding domain libraries.

Results
An algorithm for methodical design of binding domain libraries for oligonucleotide synthesis
To evaluate the possibility of a methodical approach, I designed a spreadsheet and
algorithms to analyze any given sequence and generate a library of oligonucleotides within given
parameters. This system can facilitate a methodical, high-throughput screening by generating a
library of any size using any input sequence. I considered several factors for the primary design of
the system: input sequence length, binding domain length, interval between the start of binding
domains, the starting position within the input sequence, requisite sites for cloning, and organization
of the output. Through a combination of these parameters, either a pilot screen or a tremendously
complex library can be generated.

Scripting excel to determine reverse compliment of a nucleotide sequence
In deoxyribose nucleic acid biology, adenine “A” pairs with thymine “T” and guanine “G”
pairs with cytosine “C” (Watson & Crick, 1953). This complementary nature of deoxyribose nucleic
acid poses a challenge to the handling of character strings containing DNA sequences. The
Bioconductor package Biostrings for the programming language R contains several specialized
functions, including determining DNA complementarity (Pagès, Aboyoun, Gentleman, & DebRoy,
2017). However, Excel does not contain such functions. To facilitate analysis within this
spreadsheet in a manner that would be most beneficial to the goal of library design, I wrote a script
that could handle the processing of nucleotides to determine reverse complementarity (Figure 4.1).
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Figure 4.1 A function for DNA reverse complementarity in Visual Basic for Applications. This function
accepts an input character string, determines its length, and then runs an iterative loop from the end to
the beginning of the string. The loop compares each character against the Watson-Crick complement
and appends the complement to a variable string. The function then returns the complete reverse
complement.

The reverse complement function, called Swap(), first determines the length of a given
input sequence. Then an iterative loop is performed which begins at the character at the end of the
input sequence. This character is compared against the complementary nucleotide base pairings.
If a match is found, the complementary nucleotide is noted and appended to a new string. The loop
then performs the next iteration in which the character at the end -1 position is analyzed, and so
on, until the loop has run through the entire input sequence. Then it returns the complete reverse
complemented value.
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To automate the spreadsheet, most fields are pre-filled with select functions. The
PositionNum column analyzes the Start position input, and each subsequent row increments the
position count by the interval input by the user. This column and, all others that follow, are pre-filled
through the 100,000th row, thus allowing a library of maximum 100,000 oligos. Additionally, the
second column uses the =MID() function, the current PositionNum, and the input OligoSize to parse
the target sequence and return a sequence of the desired length at the desired position within the
target. The third column appends any desired extra sequences such as restriction enzyme site
overhangs for direct compatibility into digested vectors. The fourth column is filled with the Swap()
function and performs reverse complementarity on the second column. This generates the “bottom”
oligo that will be used for cloning. Finally, the fifth column appends extra sequences as before. The
final spreadsheet therefore automatically generates the entire library through 100,000 oligos
whenever changes are made to the input sequence or any of the parameters.

Cohort processing for simplified oligo synthesis ordering
Commercially available systems for nucleotide synthesis allow for ordering large quantities
of oligonucleotides. On a high-throughput system, copying a column of thousands of rows into an
online ordering form with a limited number of rows would be a time-consuming task. Often, these
ordering systems require sequences to be placed in the context of cluster plates such as 96 or 384well format. To facilitate the transfer of any number of sequences generated by the algorithm to
any desired format, I designed a second function that would parse the output column from a given
input sequence and split the oligos into groups of a size specified by the user (Figure 4.2).
The cohort processing function begins with static numbers that correspond to cell fields to
the right of the initial output column. The function then determines how many oligos have been
designed based on the input parameters and how many oligos should be grouped per cohort based
on the value entered in the Cohort Size field. These values are then used to run an iterative loop
that will separate the oligos into columns. Each column contains the specified number of oligos.
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Figure 4.2 A function for grouping oligonucleotide libraries by a specified quantity. The Button1_Click()
function is called from the Pick Cohorts button. This function parses the spreadsheet to determine how
many oligos have been designed, analyzes the size of the output cohorts as determined by the user,
then triggers an iterative loop. This loop will separate the oligos into columns that each contain the
specified quantity.
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Analysis of CEP290 for methodical design of a binding domain library
For a target such as CEP290 intron X-27, the region of interest is 4,188 nucleotides in
length from the flanking nucleotides of exon X and exon 27. In the case of my double digest library,
the fragments were abutted end-to-end. Additionally, a binding domain size of 150bp was
considered to be ideal (Puttaraju et al., 2001). Interestingly, the best performing binding domain
from my screen was 147 nucleotides in length. Using the algorithm designed here, a library of endto-end domains consisting of 150 nucleotides each and starting from the 5’-most nucleotide would
contain 28 150bp oligos, and the 3’-most oligo would overlap the 3’ splice site (Figure 4.3).

Figure 4.3 A spread-sheet and algorithm for high-throughput design of binding domain libraries. A
sequence of interest can be copied into the Target field. CEP290 intron 27-X is show as an example.
Additional parameters to modify include: Oligo Size, Interval between oligos, Start position of oligo
design within the target sequence, 5’ and 3’ appended sequences, and cohort sizes for re-organizing
output data. Yellow field indicates common customizations, tan indicates rare changes, light grey
indicates automatic outputs, and dark grey indicates a static field.
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Discussion
Library design for pre-mRNA trans-splicing approaches is often subject to the conditions
of the sequence that is being analyzed. Various studies have approached design using rational,
random, or restriction digests, but regardless of method, none have achieved a substantial
improvement to pre-mRNA trans-splicing molecule efficacy. The properties of binding domains
have not been subject to a methodical review comparing sequence composition, relative location,
overlap of known RNA binding proteins, sequence length and related chemistry, and other
biochemical factors. The perfect experiment would be to assess every possible combination of size
and location within a target sequence. However, like many challenges in scientific study and
statistical assessments, the number of possible combinations becomes too large for a reasonably
sized experiment.
High-throughput workflows offer a chance to overcome some of these insurmountable
challenges. Automated flow cytometers and plate luminescence readers can enhance the speed
of library analysis for screens with the fluorescence reconstitution assay. Designing large libraries
in a methodical manner would typically require copying sections from a nucleotide sequence and
pasting these into a spreadsheet or order form. If, instead of an end-to-end approach for screening
putative binding domains, one were to choose some level of overlap such that the start of each
150bp domain was only 50 nucleotides apart, then the size of the library grows substantially. The
algorithm designed here can calculate this complexity by simply changing the output parameters.
Regardless of the size of the final output, this algorithm can help customize the designed
oligos to facilitate rapid ordering for synthesis. Future studies using combinations of size and
overlaps will help determine considerations for binding domain design. For example, a screen of
200 nucleotide domains 100 nucleotides apart may identify a peak of activity. By then designing a
sub-screen of 100 nucleotides 50 nucleotides apart, the “core” of activity can be refined. Studying
these putative cores in the context of several target regions may enrich our understanding of the
biology of binding domains used in pre-mRNA trans-splicing approaches for gene editing.
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Materials and Methods
All spreadsheet calculations were performed with Microsoft Excel. Scripting was written
within the Visual Basic for Applications programming environment of Microsoft Excel. Algorithm
functions were written using the Developer options and Visual Basic for Applications built into Excel.
The spreadsheet was designed so that a Target sequence (a character string consisting of only the
letters A, T, G, and C) of any length could be entered into cell C1. The input TargetSize (length of
the character string) was calculated in cell C2 with the function “=LEN(C1)”. A user can enter an
integer for the desired “OligoSize” into cell C4, an integer for the “Interval” between oligos into cell
C5, and an integer for the “StartPosition” within the Target into cell C6. Optionally, a user can also
enter characters into cells D6 and E6 to append sequences to the output oligos for purposes of
adding elements for cloning, and can enter an integer into cell J5 to select a cohort size for later
sorting of output into groupings of a given size. Fields B9:F100000 were prefilled with code
designed to automatically compute each oligo. This allows maximum generation of a library
containing ~100,000 oligos.
The following specific cells are prefilled:
o

PositionNumber: Cell B9 was filled with the function “=C6” to correspond to the “StartPosition”.
Cell C9 and all subsequent cells in the column were filled with the function
“=IF(B9<$C$2,B9+C$5,"")” such that the function refers to the cell above it within the
column and would output the value of the StartPosition + Interval in cell C9 and
LastPosition + Interval in D9.

o

OligoBottom: cell C9 was filled with the function “=IF(B9="","",MID($C$1,B9,C$4))” which
would parse the Target sequence and output the characters ranging from the current
PositionNumber through the OligoSize.

o

BottomWOverhang: cell D9 was filled with the function “=IF(C9="","",D$6&C9)” which would
append the optional sequences for cloning.

o

OligoTop: cell E9 was filled with the novel function “=swap(C9)” which calls a function I wrote
to determine the reverse compliment of the detected oligo.
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o

TopWOverhang: cell F9 was filled with the function “=IF(C9="","",F$6&E9)” which would
append the optional sequences for cloning to the calculated OligoTop.

o

Pick Cohorts: A VBA_Button was designed and the “click” response was set to call the
Button1_Click function, which was designed to call the cohort processing function, parse
the output oligo listing, and separate results into cohorts of a size entered in cell J5.
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CHAPTER 5 Discussion

Proof-of-concept editing of CEP290 and ABCA4
RNA editing by pre-mRNA trans-splicing is currently being evaluated as a therapeutic
strategy for the treatment of numerous diseases that are otherwise not candidates for traditional
gene augmentation with recombinant adeno-associated virus. In this work, I identified trans-splicing
molecules for both CEP290 and ABCA4, which are causative for the most prevalent forms of Leber
Congenital Amaurosis and juvenile macular degeneration, respectively, in addition to several other
diseases. While screening trans-splicing molecules for both genes, I achieved approximately 10%
GFP positive cells with a GFP reconstitution assay, indicating that trans-splicing was occurring but
at a low efficiency. Despite the low frequency as a percent of total cells, I was able to utilize the top
identified binding domain sequence to facilitate gene editing of CEP290 both in vitro, targeting
endogenous transcripts in HEK293T cells, and in vivo, in a humanized mouse model.
Contrarily, my study of ABCA4 trans-splicing was more limited because of lack of in vivo
and in vitro expression models. Despite being a desirable target due to a high population
prevalence, establishing a proof-of-concept for retinal trans-splicing of big genes mandated that I
first proceed with CEP290. For CEP290, ubiquitous expression in human cell lines allowed
assessment of endogenous targeting. I also took advantage of a mini-gene mouse model for
CEP290 which was previously generated for a study assessing a disease causing mutation that
was predicted to drive inclusion of exon X. As is often the case in science, that study, and similar
studies by other groups, were complicated by slightly different spliceosome recognition in the
mouse as compared to humans. Regardless of this variance as it pertains to exon X, I was able to
use the model to demonstrate photoreceptor specific trans-splicing to the CEP290 mini-gene in
vivo.

Characterizing endogenous expression of ABCA4
The success of editing CEP290 suggests that ABCA4, if able to be successfully modeled
for endogenous expression, would likely provide at least similar results of RNA editing. Profiling
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multiple cell lines with the hopes of finding endogenous expression of ABCA4 yielded interesting
insights into alternative transcripts and putative new peptides. Other groups have reported
identifying ABCA4 alternative peptides but have done little to classify their sequences or identify
how the coding transcript arises. In my studies, I found that a band commonly observed, but often
disregarded as non-specific, is likely a peptide encoded by ABCA4. Indeed, the predicted transcript
is the only alternative protein coding DNA sequence present in the Ensembl database for ABCA4.
I was also able to retrospectively elucidate the existence of this ABCA4Alt transcript in multiple
tissue types from RNA-Seq data sets. This finding highlights the importance of analyzing data
specifically for what it shows. In the case of RNA-Seq, the most current version of the Human
Protein Atlas shows only the average of transcript detection across a whole gene. The display of
RNA-Seq alignment to known transcripts on Ensembl was phased out when the older data set was
merged with another database. Concurrently, the current version shows expression of ABCA4 as
highest in epididymis, but after tracing the reads, this actually reflects expression of only the 3’most exons. There is no transcript on Ensembl that would match such a minimal region of
expression. This could be yet another alternate isoform not yet characterized.
The role of ABCA4Alt may be insignificant or the peptide may provide a new biological
insight into this gene. Beyond considerations for other roles of ABCA4, the field of gene therapy
must always consider alternative transcripts. These are critical to both gene augmentation and
gene editing. Identifying alternate transcripts based on isolated tissue types used to generate
current databases is still not ideal. The retina is rarely isolated as a separate source of RNA despite
being one of the earliest formations during development. The Clontech brand Human Multiple
Tissue Panels of cDNA have samples from most major organs including a sub-panel for digestive
tract, but the eye is absent from all of these. With the FDA approval of Luxturna for commercial
sale, this may be an opportune time to ensure that the retina, or at least the eye as a whole,
becomes a commonly considered organ for specific analysis, much like the duodenum and jejunum
are separately categorized within the digestive system.
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Modeling and correcting phenotypes
Beyond simply being able to model RNA editing, it is also important that a study
demonstrates correction of a phenotype. While CEP290 is ubiquitously expressed and endogenous
trans-spicing can be assessed, neither the HEK293T wild-type cells nor the mouse mini-CEP290
model harbored a phenotype that would be amendable for rescue. To address this, I used a
targeted endonuclease to engineer a derivative of the HEK293T cell line that is deficient in CEP290.
Similar to reports of LCA10 patient-derived induced pluripotent stem cells, this HEK293T-derived
line had decreased cilia formation and substantially lower levels of CEP290 protein. With one
mutation being a frameshift and the other an in-frame deletion, residual protein levels were
predicted to be only half reduced. Oddly, the level of CEP290 was lower than 50%. That the protein
level was less than half suggests that the three deleted amino acids may be critical to protein
stability. Also, during the screening of single cell clones, none identified generated a complete loss
of CEP290. Though the screening was not exhaustive, this may be a reflection of the importance
of the protein for cellular function. The phenotype of the CEP290 deficient cell line might be further
enhanced by causing a mutation in a second locus of CEP290. This would also help answer if a
complete ablation of CEP290 would be viable in vitro.
While generating a phenotype for CEP290 deficiency can be achieved by manipulating
cultured cells, modeling a phenotype for ABCA4 is still challenging. In the promoter activation
studies, I showed that Cas9 technologies can be used to substantially increase gene expression of
ABCA4. Despite the RNA increase, I was unable to detect translated protein. The absence of
protein could be the result of several confounding factors. In this pilot dCas9-VPR study, I used
one primer pair in the 5’ region of ABCA4Full to detect expression. Without activation, HEK293T
have minimal, but still detectable, amounts of ABCA4 exon 8 – 9 junction. Since there is a lack of
visible protein, this is likely the result of leaky gene silencing and the transcript or protein may be
labeled as inappropriate and degraded.
The level of gene activation by dCas9-VPR may be insufficient to visualize protein. In
HEK293T cells, ABCA4 has Ct values of 35-37 which are brought down to 28-29 after activation,
indicating a 300-fold increase. Despite that shift, the ΔCt relative to β-2-microglobin indicates a
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more than 1000-fold difference in expression of this induced ABCA4 exon 8 – 9 detection and of
the housekeeping gene. As dCas9-VPR and guide prediction technologies improve, it will be
interesting to determine if there is a correlation between Ct values and protein detection. More
importantly for this study, the level of RNA expression must be enough to not only express
detectable protein but also must be in sufficient abundance to allow for pre-mRNA editing.
With proof-of-concept gene expression induction in HEK293T, the next step is to evaluate
induction of gene expression in patient-derived induced pluripotent stem cells. When compared
against healthy “wild-type” control cell lines, these cells will be a model of ABCA4 expression with
the opportunity to show correction of a disease-associated phenotype. However, certain promoters
including cytomegalovirus, used in the HEK293T dCas9-VPR study, are not active in these
pluripotent cells (Jason A. Mills, personal communication). Changing the promoter driving the
dCas9-VPR cassette may be a limiting challenge itself because the lentivirus vector is already at
capacity, so alternative promoters must be equal to or smaller than CMV. In collaboration with
Devin McDougald and Dr. Jason A. Mills, we performed a pilot lentivirus transduction of induced
pluripotent stem cells followed by puromycin selection and showed that an alternative small
promoter, the core of the EF1α promoter, can drive expression of GFP through at least two weeks.
With these preliminary findings we can now move to test if the dCas9-VPR can drive expression of
ABCA4 in these patient-derived cells, and assess if it does so to high enough levels to test transsplicing molecules.
The challenge of having sufficient target pre-mRNA for editing is a direct reflection on the
low efficiency of the pre-mRNA trans-splicing molecules. Efficiency of the RNA editing process is
likely inversely proportional to the relative amount of target necessary for gene editing.
Hypothetically, a more efficient PTM could target genes of lower abundance.

Improving PTM genome composition
Once we have strong models with phenotypes, the next obstacle is achieving not only
detectable editing but also attaining physiologically relevant levels of corrected RNA. The premRNA trans-splicing molecules used in my studies were sufficient for proof-of-concept, but major
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improvements will be required before they could be used in a therapeutic setting. Improvements to
efficiency are the focus of all research groups studying trans-splicing. One avenue of pursuit is to
identify secondary elements that could reduce the competency of competitor RNA species, such
as the endogenous splice site within the intron being targeted. For example, anti-sense
oligonucleotides were tested in a study of KRT14 trans-splicing. The authors utilized a split-GFP
reporter system of the same design used in my studies. In addition to the mini-gene and transsplicing

molecule,

the

authors

additionally

co-transfected

anti-sense

oligonucleotides

complementary to upstream regions of the target intron and were able to increase the percent of
GFP positive cells from 10% to 40% (Liemberger et al., 2018). Importantly, expression of the
KRT14 gene is not detected in the HEK293T line used for this screen (Thul et al., 2017). In this
particular study, the authors did not evaluate the potential of this combination to trans-splice to
endogenous transcripts in the keratinocyte cell line originally used to validate the KRT14 binding
domain (Wally et al., 2010). It will be interesting to see the activity of their combined approach in
such relevant models for the effects on endogenous targets when compared to mini-gene targets.
In chapter 2, I identified a peptide being translated from the PTM genome without transsplicing. This type of expression was unexpected and is undesired because a partial peptide can
be immunogenic. Other groups have demonstrated that ablating the polyadenylation signal
sequence will also ablate translation in the absence of successful trans-splicing, but that effect was
not observed with my system. Beyond the poly-adenylation signal, splice enhancer sequences
have also been investigated by other groups to ensure that pre-mRNA is rapidly picked up by
spliceosome components and not allowed to become a mature messenger RNA. One such
sequence, DISE FGFR2, was shown to increase trans-splicing of dystrophin, but in the context of
my CEP290 PTM, the sequence conferred no significant improvements. Many of these elements
may be context-specific and so profiling them may always come with caveats. As combination
efforts such as these are explored, the field will need to compare the composition and elements
used in the most efficacious molecules to identify commonalities between the best performing
motifs. So far, a thorough analysis has not been performed to assess all these putative
improvements within one system. Perhaps the most optimal method of determining components to
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add to a PTM will be to aggregate a database of elements predicted to be beneficial to the RNA
editing reaction and evaluate them in the context of one gene target. This type of large dataset for
additional PTM component analysis would best be achieved with a high-throughput screening
system such as automated GFP positivity cell counting. High-throughput screens are likely the best
way to tackle the complexity of trans-splicing. Additionally, given the packaging limit of AAV, the
trade-off between including more elements and the size of those elements vs. the optimal size of
the partial coding DNA sequence will also need to be considered.

Binding domain optimization
In addition to including extra elements in the PTM genome, the binding domain sequences
themselves likely have more secrets to reveal. In early studies, binding domain length was
evaluated in an incremental manner. This study started with a 3’ PTM overlapping the 3’ splice site
of a target intron and simply appended more upstream complementary sequence to arrive at the
conclusion that greater than 200 nucleotides failed to improve efficacy (Puttaraju et al., 2001). This
study was not entirely methodical as the core sequence wasn’t thoroughly vetted by then removing
complementary sequence from the downstream end.
Sequence selection of binding domains in early trans-splicing studies was achieved by
rational design after evaluating predicted folding patterns of RNA and relative location within a
target sequence (Puttaraju et al., 1999). In collaboration with Dr. Lloyd Mitchell, the first sequences
tested in my CEP290 study were also rationally designed. However, these putative binding domains
showed no GFP reconstitution. This led me to pursue the more randomized binding domain
generation by fragmentation. I selected restriction enzymes that would yield fragments with a
median size around the published ideal of 200 nucleotides. This low throughput screen yielded
approximately the same success as the sonication screens used in other studies that generated
thousands of fragments.
The challenge so far is that the rational and random design methods have not yielded
promising and consistent contextual rules for predicting efficient motifs in the future. It may be
possible that such rules do not exist, but it is more likely that the activity of a specific motif results
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from a combination of RNA biological properties. These properties can include intrinsic factors such
as nucleotide composition and folding patterns, as well as extrinsic factors such as RNA-binding
protein recognition sites, the composition of and location within the target sequence, and
competition from endogenous splice sites. With neither rational nor random systems yielding high
potency, the next step of optimizing binding domain generation may be to perform a screen
designed with a methodical process to cover all possible areas of a target sequence. This would
allow for a comparison of binding domain length against complementarity position within a target
sequence. Additionally, it would be important to extrapolate such a study to several target sequence
contexts to identify patterns across data sets.

High-throughput methodical approaches
As a part of my dissertation, I have designed a workflow that can be used for future studies
of any big gene to establish a foundational pre-mRNA trans-splicing therapy. The combination of
the maximum benefit table and the OligoDesigner allows a streamlined high-throughput workflow
to be applied. Once a gene is identified as causative to a disease, it can be screened by in silico
analysis of the coding sequence. This is the current standard practice for gene augmentation.
However, when the gene exceeds the packaging capacity of a vector such as AAV, gene
augmentation is no longer an option. Evaluating the transcript in a maximum benefit table allows
for a quick visualization of where a trans-splicing strategy could be targeted.
Once a target intron is identified, a pilot library can be synthesized by entering the intron
sequence into the OligoDesigner with some basic parameters. Depending on the parameters, this
pilot library can present a wide-field view of efficacy. Granted, there is much unknown about binding
domain biology and these unknown factors can create false negatives when using too broad of a
screen. For instance, in my CEP290 screen, BD_07 was the highest performing motif, while the
adjacent upstream BD_06 was minimally better than the untargeted reporter. It remains to be seen
if a fragment that overlapped between BD_06 and BD_07 would be improved or worsened
compared to BD_07. Once a preliminary binding site is identified, determining the margins of
minimally necessary sequence may help to distill a sequence down to the most essential parts.
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With the OligoDesigner, iterative libraries that can ask these kinds of questions can also
be easily and rapidly designed. High-throughput methods will be needed to then perform the
screens to identify what, if anything, determines an efficacious binding domain. Whether or not
standard parameters can be determined, the algorithm will be useful for future applications of library
design.

Conclusion
Gene therapy has made incredible advances over the last decade and the march forward
is gaining speed. Poised with the knowledge of challenges and risks faced in early trials, the field
is making safer vectors and has achieved regulatory approval for several products. Expanding the
repertoire of available tools is more important than ever and improving the bench-to-bedside
timeline will be fundamental to future studies. In this dissertation, I have shown that we can rapidly
design pre-mRNA trans-splicing editing strategies for the genes CEP290 and ABCA4, and that this
design approach can be applied to other genes that exceed the capacity of gene therapy vectors.
Ongoing studies and improvements to pre-mRNA trans-splicing molecules and binding domain
design will hopefully bring this strategy to an efficiency level where it can be employed as a clinical
treatment in the future.
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